<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        84-6-99
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1999
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DUROGESIC TTS 75 Ug-HOUR
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FENTANYL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        75
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Transdermal use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Transdermal patch
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Box
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Controlled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        276.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="JANSSEN PHARMACEUTICA N.V." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            JANSSEN PHARMACEUTICA N.V.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            JANSSEN PHARMACEUTICA N.V
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N02AB03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The name of your medicine is DUROGESIC</p><p>&nbsp;</p><p>The patches help relieve pain that is very bad and long-lasting:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in adults who need continuous pain treatment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in children above 2 years of age who are already using opioid medication and who need continuous pain treatment.</p><p>&nbsp;</p><p>DUROGESIC contains a medicine called fentanyl. It belongs to a group of strong painkillers called opioids.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use DUROGESIC if</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are allergic to fentanyl or any of the other ingredients of this medicine (listed in section 6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have pain which lasts only for a short period, such as sudden pain or pain after having an operation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have breathing difficulties, with slow or shallow breathing</p><p>Do not use this medicine if any of the above apply to you or your child. If you are not sure, talk to your doctor or pharmacist before using DUROGESIC.</p><p>&nbsp;</p><p>Warnings and precautions</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:65.3pt;margin-top:13pt;width:464.9pt;height:93.4pt;z-index:-15703040;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:.95pt;margin-right:10.9pt;
     margin-bottom:0in;margin-left:23.35pt;margin-bottom:.0001pt;text-indent:
     -.25in;mso-list:l2 level1 lfo1;tab-stops:23.35pt 23.4pt'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span>DUROGESIC can have
     life-threatening side effects in people who are not already regularly
     using prescribed opioid<span style='letter-spacing:-.15pt'> </span>medicines.<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:12.6pt;margin-bottom:
     0in;margin-left:23.35pt;margin-bottom:.0001pt;text-indent:-.25in;
     mso-list:l2 level1 lfo1;tab-stops:23.35pt 23.4pt'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span>DUROGESIC is a
     medicine that could be life-threatening to children, even if the patches
     have been used. Bear in mind that a sticky patch (unused or used) could be
     tempting to a child and if it sticks to a child’s skin or they put it in
     their mouth, the result may be<span style='letter-spacing:-1.05pt'> </span>fatal.<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:13.95pt;
     margin-bottom:0in;margin-left:23.35pt;margin-bottom:.0001pt;text-indent:
     -.25in;mso-list:l2 level1 lfo1;tab-stops:23.35pt 23.4pt'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span>Store this medicine in
     a safe and secure place, where other people cannot access it - see section
     5 for more<span style='letter-spacing:-.15pt'> </span>information.<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left" style="width:1188.83px"><tbody><tr><td style="width:1px">&nbsp;</td></tr><tr><td style="width:1px">&nbsp;</td><td style="width:1187.17px"><img width="623" height="129" alt="Text Box: •	DUROGESIC can have life-threatening side effects in people who are not already regularly using prescribed opioid medicines.
•	DUROGESIC is a medicine that could be life-threatening to children, even if the patches have been used. Bear in mind that a sticky patch (unused or used) could be tempting to a child and if it sticks to a child’s skin or they put it in their mouth, the result may be fatal.
•	Store this medicine in a safe and secure place, where other people cannot access it - see section 5 for more information.
" src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Patch sticking to another person</strong></p><p>The patch should be used only on the skin of the person for whom it has been prescribed. There have been reports of patches accidentally sticking to a family member while in close physical contact or sharing the same bed as the person wearing the patch. A patch accidently sticking to another person (particularly a child) can cause the medicine in the patch to go through the skin of the other person and cause serious side effects such as breathing difficulties, with slow or shallow breathing which may be fatal. In case the patch sticks to the skin of another person, take the patch off right away and get medical attention.</p><p>&nbsp;</p><p>Take special care with DUROGESIC</p><p><strong>&nbsp;</strong></p><p><strong>Talk to your doctor or pharmacist before </strong>using this medicine if any of the following apply to you - your doctor may need to check you more closely if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have ever had problems with your lungs or breathing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have ever had problems with your heart, liver, kidneys, or low blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have ever had a brain tumour.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have ever had persistent headaches or a head injury.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are elderly - you may be more sensitive to the effects of this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a condition called &lsquo;myasthenia gravis&rsquo; in which muscles become weak and tire easily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You or anyone in your family have ever abused or been dependent on alcohol, prescription medicines or illegal drugs (&ldquo;addiction&rdquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are a smoker.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have ever had problems with your mood (depression, anxiety or a personality disorder) or have been treated by a psychiatrist for other mental illness.</p><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before using DUROGESIC.</p><p>&nbsp;</p><p><strong>While using the patch, tell your doctor if you have breathing problems while sleeping. </strong>Opioids like DUROGESIC can cause sleep-related breathing disorders such as sleep apnoea (breathing pauses during sleep) and sleep-related hypoxaemia (low oxygen level in the blood). Tell your doctor if you, your partner or carer notice you have any of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathing pauses during sleep</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; night awakening due to shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulties staying asleep</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive drowsiness during the day. Your doctor may decide to change your dose.</p><p>&nbsp;</p><p>While using the patch, tell your doctor if you notice a change in the pain you are feeling. If you feel:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your pain is no longer relieved by the patch</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an increase in pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; there is a change in how you feel the pain (for example, you feel pain in another part of your body)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain when something touches your body that you wouldn&rsquo;t expect to hurt you.</p><p>&nbsp;</p><p>Do not change the dose yourself. Your doctor may decide to change your dose or treatment.</p><p>Side effects and DUROGESIC</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DUROGESIC may make you unusually drowsy, and make your breathing more slow or shallow. Very rarely these breathing problems can be life-threatening or even fatal, especially in people who have not used strong opioid painkillers (like DUROGESIC or morphine) before. If you, or your partner or carer, notice that the person wearing the patch is unusually drowsy, with slow or shallow breathing:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take the patch off.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call a doctor, or go to your nearest hospital straight away.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep the person moving and talking as much as possible.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you get a fever while using DUROGESIC, tell your doctor - this may increase the amount of medicine that passes through your skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DUROGESIC may cause constipation, talk to your doctor or pharmacist for advice on how to prevent or relieve constipation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Repeated, long-term use of the patches may make the medicine less effective (you get used to it, or you may become more sensitive to pain), or you may become dependent on it. Increasing the dose of your patches may help to further reduce your pain for a while, but it may also be harmful. If you notice that your medicine becomes less effective, talk to your doctor. Your doctor will decide whether it is better for you to increase the dose or to gradually decrease your use of DUROGESIC. Also if you have concern that you may become dependent, you can consult your doctor on this.</p><p>See section 4 for a full list of possible side effects.</p><p>&nbsp;</p><p>When you are wearing the patch do not expose it to direct heat such as heating pads, electric blankets, hot-water bottles, heated water beds or heat or tanning lamps. Do not sunbathe, have long hot baths or saunas or use hot whirlpool spa baths. If you do, you may increase the amount of medicine you get from the patch.</p><p>&nbsp;</p><p>Withdrawal symptoms when stopping DUROGESIC</p><p>Do not suddenly stop taking this medicine. Withdrawal symptoms such as restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, loss of appetite, shaking, shivering or sweating may occur. If you want to stop taking this medicine, talk to your doctor first. Your doctor will tell you how to do this, usually by reducing the dose gradually so that any unpleasant withdrawal effects are kept to a minimum.</p><p>&nbsp;</p><p>Other medicines and DUROGESIC</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines that you buy without a prescription or herbal medicines. You should also tell your pharmacist that you are using DUROGESIC if you buy any medicines from your pharmacy.</p><p>&nbsp;</p><p>Your doctor will know which medicines are safe to take with DUROGESIC. You may need to be closely monitored if you are taking some of the types of medicines listed below or if you stop taking some of the types of medicines listed below, as this may affect the strength of DUROGESIC you need.</p><p>&nbsp;</p><p>In particular, tell your doctor or pharmacist if you are taking:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other medicines for pain, such as other opioid painkillers (such as buprenorphine, nalbuphine, or pentazocine) and some painkillers for nerve pain (gabapentin and pregabalin).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for helping you sleep (such as temazepam, zaleplon, or zolpidem).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines to help you calm down (tranquillisers, such as alprazolam, clonazepam, diazepam, hydroxyzine, or lorazepam) and medicines for mental conditions (anti-psychotics, such as aripiprazole, haloperidol, olanzapine, risperidone, or phenothiazines).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for relaxing your muscles (such as cyclobenzaprine or diazepam).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some medicines used to treat depression called SSRIs or SNRIs (such as citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, or venlafaxine). &ndash; see below for more information.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some medicines used to treat depression or Parkinson&rsquo;s disease called MAOIs (such as isocarboxazid, phenelzine, selegiline, or tranylcypromine).You should not take DUROGESIC within 14 days of stopping these medicines. &ndash; see below for more information.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some antihistamines, especially ones that make you sleepy (such as chlorpheniramine, clemastine, cyproheptadine, diphenhydramine, or hydroxyzine).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some antibiotics used to treat infection (such as erythromycin or clarithromycin).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines used to treat fungal infection (such as itraconazole, ketoconazole, fluconazole, or voriconazole).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines used to treat HIV infection (such as ritonavir).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines used to treat an irregular heartbeat (such as amiodarone, diltiazem, or verapamil).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines to treat tuberculosis (such as rifampicin).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some medicines used to treat epilepsy (such as carbamazepine, phenobarbital, or phenytoin).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some medicines used to treat nausea or motion sickness (such as phenothiazines).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some medicines used to treat heartburn or ulcers (such as cimetidine).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some medicines used to treat angina (chest pain) or high blood pressure (such as nicardipine).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some medicines used to treat cancer of the blood (such as idelalisib).</p><p>&nbsp;</p><p>DUROGESIC with antidepressants</p><p>The risk of side effects increases if you are taking medicines such as certain antidepressants. DUROGESIC may interact with these medicines and you may experience changes to mental status such as feeling agitated, seeing, feeling, hearing, or smelling things that are not there (hallucinations) and other effects such as changing blood pressure, fast heartbeat, high body temperature, overactive reflexes, lack of coordination, muscle stiffness, nausea, vomiting and diarrhoea (these could be signs of Serotonin Syndrome). If used together, your doctor may want to closely monitor you for such side effects in particular when starting treatment or when the dose of your medicine is changed.</p><p>&nbsp;</p><p><strong>Use with central nervous system depressants, including alcohol and some narcotic drugs </strong>Concomitant use of DUROGESIC and sedative medicines such as benzodiazepines or related drugs increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening. Because of this, concomitant use should only be considered when other treatment options are not possible.</p><p>&nbsp;</p><p>However if your doctor does prescribe DUROGESIC together with sedative medicines the dose and duration of concomitant treatment should be limited by your doctor.</p><p>&nbsp;</p><p>Please tell your doctor about all sedative medicines you are taking, and follow your doctor&rsquo;s dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms.</p><p>&nbsp;</p><p>Do not drink alcohol while using DUROGESIC unless you have talked to your doctor first.</p><p>&nbsp;</p><p>Operations</p><p>If you think that you are going to receive anaesthesia tell your doctor or dentist that you are using DUROGESIC.</p><p>&nbsp;</p><p>Pregnancy and breastfeeding</p><p>If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.</p><p>&nbsp;</p><p>DUROGESIC should not be used during pregnancy unless you have discussed this with your doctor.</p><p>&nbsp;</p><p>DUROGESIC should not be used during childbirth as the medication can affect the breathing of the newborn child.</p><p>&nbsp;</p><p>Prolonged use of DUROGESIC during pregnancy can cause withdrawal symptoms (such as high- pitched cry, jitteriness, fits, poor feeding and diarrhoea) in your newborn baby that could be life-threatening if not recognised and treated. Talk to your doctor immediately if you think your baby may have withdrawal symptoms.</p><p>&nbsp;</p><p>Do not use DUROGESIC if you are breastfeeding. You should not breastfeed for 3 days after removing your DUROGESIC patch. This is because the medicine may pass into breast milk.</p><p>&nbsp;</p><p>Driving and using machines</p><p>DUROGESIC can affect your ability to drive and use machines or tools as it may make you sleepy or dizzy. If this happens, do not drive or use any tools or machines. Do not drive while using this medicine until you know how it affects you.</p><p>&nbsp;</p><p>Talk to your doctor or pharmacist if you are not sure whether it is safe for you to drive while taking this medicine.</p><p>&nbsp;</p><p>.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Your doctor will decide which strength of DUROGESIC is most suitable for you, taking into account the severity of your pain, your general condition and type of pain treatment that you have received so far.</p><p>&nbsp;</p><p>Using and changing the patches</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There is enough medicine in each patch to last <strong>3 days (72 hours).</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should change your patch every third day, unless your doctor has told you differently.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always remove the old patch <strong>before </strong>applying a new one.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always change your patch at the <strong>same time </strong>of day every 3 Days (72 hours).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are using more than one patch, change all your patches at the same time.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Make a note of the day, date and time you apply a patch, to remind you when you need to change your patch.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The following table shows you when to change your patch:</p><p>&nbsp;</p><p>Apply your patch on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change your patch on</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Monday&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; Thursday</p><p><!--[if gte vml 1]><v:shape id="image2.png" o:spid="_x0000_s1034"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:238.4pt;margin-top:3.3pt;width:21.5pt;height:7.95pt;z-index:-16797184;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="29" height="11" src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" />Tuesday&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Friday</p><p><!--[if gte vml 1]><v:shape id="image3.png" o:spid="_x0000_s1033"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:238.4pt;margin-top:3.25pt;width:21.5pt;height:7.85pt;z-index:-16796672;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="29" height="11" src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gif" />Wednesday&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Saturday</p><p><!--[if gte vml 1]><v:shape id="image4.png" o:spid="_x0000_s1032"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:238.4pt;margin-top:3.6pt;width:21.5pt;height:7.95pt;z-index:-16796160;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image007.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="29" height="11" src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image008.gif" />Thursday&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Sunday</p><p><!--[if gte vml 1]><v:shape id="image5.png" o:spid="_x0000_s1031"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:238.4pt;margin-top:4.05pt;width:21.5pt;height:7.85pt;z-index:-16795648;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image009.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="29" height="11" src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image010.gif" />Friday&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Monday</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1030"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:238.4pt;margin-top:3.85pt;width:21.5pt;height:7.95pt;z-index:-16795136;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image007.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="29" height="11" src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image011.gif" />Saturday&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;&nbsp;Tuesday</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1029"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:238.4pt;margin-top:3.35pt;width:21.5pt;height:7.95pt;z-index:-16794624;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image007.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="29" height="11" src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image011.gif" />Sunday&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Wednesday</p><p>&nbsp;</p><p>Where to apply the patch Adults</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Apply the patch on a flat part of your upper body or arm (not over a joint).</p><p>&nbsp;</p><p>Children</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always apply the patch to the upper back to make it difficult for your child to reach it or take it off.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Every so often check that the patch remains stuck to the skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is important that your child does not remove the patch and put it in their mouth as this could be life-threatening or even fatal.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Watch your child very closely for 48 hours after:</p><p>-&nbsp;&nbsp;&nbsp; The first patch has been put on</p><p>-&nbsp;&nbsp;&nbsp; A higher dose patch has been put on</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It may take some time for the patch to have its maximum effect. Therefore, your child might need to use other painkillers as well until the patches become effective. Your doctor will talk to you about this.</p><p>&nbsp;</p><p>Adults and Children:</p><p><strong>Do not apply the patch on</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The same place twice in a row.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Areas that you move a lot (joints), skin that is irritated or with cuts.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin that is very hairy. If there is hair, do not shave it (shaving irritates the skin). Instead, clip the hair as close to the skin as possible.</p><p>&nbsp;</p><p>Putting a patch on</p><p><strong>Step 1: Preparing the skin</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Make sure your skin is completely dry, clean and cool before you put the patch on</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you need to clean the skin, just use cold water</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use soap or any other cleansers, creams, moisturisers, oils or talc before applying the patch</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not stick a patch on straight after a hot bath or shower</p><p>&nbsp;</p><p>Step 2: Open the sachet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each patch is sealed in its own sachet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tear or cut open the sachet at the notch, shown by the arrow</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently tear or cut off the edge of the sachet completely (if you use scissors, cut close to the sealed edge of the sachet to avoid damaging the patch)</p><p><!--[if gte vml 1]><v:shape id="image6.png"
 o:spid="_x0000_i1025" type="#_x0000_t75" style='width:145.5pt;height:67.5pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image012.png"
  o:title=""/>
</v:shape><![endif]--><img width="194" height="90" src="data:image/png;base64,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" /></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grasp both sides of the opened sachet and pull apart</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take the patch out and use straight away</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep the empty sachet to dispose of the used patch later</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use each patch once only</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take the patch out of its sachet until you are ready to use it</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inspect the patch for any damage</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use the patch if it has been divided, cut or looks damaged</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Never divide or cut the patch</p><p>&nbsp;</p><p>Step 3: Peel and press</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Make sure that the patch will be covered by loose clothing and not stuck under a tight or elasticated band</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carefully peel one half of the shiny plastic backing away from the centre of the patch. Try not to touch the sticky side of the patch</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Press this sticky part of the patch onto the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the other part of the backing and press the whole patch onto the skin with the palm of your hand</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold for at least 30 seconds. Make sure it sticks well, especially the edges</p><p>&nbsp;</p><p>Step 4: Disposing of the patch</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As soon as you take a patch off, fold it firmly in half so that the sticky side sticks to itself</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Put it back in its original sachet and dispose of the sachet as instructed by your pharmacist</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep used patches out of sight and reach of children &ndash; even used patches contain some medicine that may harm children and may even be fatal</p><p>&nbsp;</p><p>Step 5: Wash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always wash your hands after you have handled the patch using clean water only</p><p>&nbsp;</p><p>More about using DUROGESIC</p><p><strong>&nbsp;</strong></p><p><strong>Everyday activities while using the patches</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The patches are waterproof</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can shower or bathe while wearing a patch, but do not scrub the patch itself</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor agrees, you can exercise or play sport while wearing the patch</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can also swim while wearing the patch, but:</p><p>-&nbsp;&nbsp;&nbsp; Don&rsquo;t use hot whirlpool spa baths</p><p>-&nbsp;&nbsp;&nbsp; Don&rsquo;t put a tight or elasticated band over the patch</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; While you are wearing the patch do not expose it to direct heat such as heating pads, electric blankets, hot-water bottles, heated water beds, heat or tanning lamps. Do no sunbathe, have long hot baths or saunas. If you do, you may increase the amount of medicine you get from the patch.</p><p>&nbsp;</p><p>How quickly will the patches work?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It may take some time for your first patch to have its maximum effect.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may give you other painkillers as well for the first day or so.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After this, the patch should help to relieve pain continuously so that you can stop taking other painkillers. However, your doctor may still prescribe extra painkillers from time to time.</p><p>&nbsp;</p><p>How long will you use the patches for?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DUROGESIC patches are for long-term pain. Your doctor will be able to tell you how long you can expect to use the patches</p><p>&nbsp;</p><p>If your pain gets worse</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your pain suddenly gets worse after placing your last patch you should check your patch. If it is no longer sticking well or has fallen off you should replace the patch (<em>See also section If a patch falls off</em>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your pain gets worse over time while you are using these patches, your doctor may try a higher strength patch, or give you additional painkillers (or both).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If increasing the strength of the patch does not help, your doctor may decide to stop the use of the patches.</p><p>&nbsp;</p><p>If you use too many patches or the wrong strength patch</p><p>If you have stuck on too many patches or the wrong strength patch, take the patches off and contact a doctor straight away.</p><p>&nbsp;</p><p>Signs of overdose include trouble breathing or shallow breathing, tiredness, extreme sleepiness, being unable to think clearly, walk or talk normally and feeling faint, dizzy or confused.</p><p>&nbsp;</p><p>If you forget to change your patch</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget, change your patch as soon as you remember and make note of the day and time. Change the patch again after <strong>3 days (72 hours) </strong>as usual.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are very late changing your patch, you should talk to your doctor because you might need some extra painkillers, but do <strong>not </strong>apply an extra patch.</p><p>&nbsp;</p><p>If a patch falls off</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If a patch falls off before it needs changing, stick a new one on straight away and make note of the day and time. Use a new area of skin on:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your upper body or arm</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your child&rsquo;s upper back</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Let your doctor know this has happened and leave the patch on for another <strong>3 days (72 hours) </strong>or as directed by your doctor, before changing the new patch as usual</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your patches keep falling off, talk to your doctor, pharmacist or nurse</p><p>&nbsp;</p><p>If you want to stop using the patches</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not suddenly stop taking this medicine. If you want to stop taking this medicine, talk to your doctor first. Your doctor will tell you how to do this, usually by reducing the dose gradually so that any unpleasant withdrawal effects are kept to a minimum. See also section 2 <em>&lsquo;Withdrawal symptoms when stopping DUROGESIC&rsquo;</em>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you stop using the patches, don&rsquo;t start again without asking your doctor first. You might need a different patch strength when you restart.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>If you or your partner, or carer, notice any of the following about the person wearing the patch, take the patch off and call a doctor, or go to your nearest hospital, straight away. You may need urgent medical treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling unusually drowsy, breathing that is more slow or shallow than expected.</p><p>Follow the advice above and keep the person who was wearing the patch moving and talking as much as possible. Very rarely these breathing difficulties can be life-threatening or even fatal, especially in people who have not used strong opioid painkillers (like DUROGESIC or morphine) before. (Uncommon, this may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden swelling of the face or throat, severe irritation, reddening or blistering of your skin. These may be signs of a severe allergic reaction. (frequency cannot be estimated from the available data)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fits (seizures). (Uncommon, this may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced consciousness or loss of consciousness. (Uncommon, these may affect up to 1 in 100 people)</p><p>The following side effects have also been reported Very common (may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea, vomiting, constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sleepy (somnolence)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&nbsp;</p><p>Common (may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reaction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty sleeping</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling anxious or confused</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seeing, feeling, hearing, or smelling things that are not there (hallucinations)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle tremors or spasms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unusual feeling in the skin, such as tingling or crawling feelings (paraesthesia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Spinning sensation (vertigo)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heartbeat feels fast or uneven (palpitations, tachycardia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Being short of breath (dyspnoea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pain or indigestion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching, skin rash or redness of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Being unable to pass urine or empty bladder completely</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling very tired, weak or generally unwell</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling cold</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swollen hands, ankles or feet (peripheral oedema)</p><p>&nbsp;</p><p>Uncommon (may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling agitated or disoriented</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling extremely happy (euphoria)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased feeling or sensitivity, especially in the skin (hypoaesthesia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of memory</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blurred vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slow heart beat (bradycardia) or low blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blue colour to the skin caused by low oxygen in the blood (cyanosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of contractions of the gut (ileus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itchy skin rash (eczema), allergic reaction or other skin disorders where the patch is placed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flu-like illness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling of body temperature change</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle twitching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty getting and keeping an erection (impotence) or problems having sex</p><p>&nbsp;</p><p>Rare side effects (may affect up to 1 in 1 000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constricted pupils (miosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stopping breathing from time to time (apnoea)</p><p>&nbsp;</p><p>The following side effects have also been reported, but their exact frequency is unknown:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lack of male sex hormones (androgen deficiency)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Delirium (symptoms may include a combination of agitation, restlessness, disorientation, confusion, fear, seeing or hearing things that are not really there, sleep disturbance, nightmares).</p><p>&nbsp;</p><p>You may notice rashes, redness or slight itching of the skin at the site of the patch. This is usually mild and disappears after you have removed the patch. If it does not, or if the patch irritates your skin badly, tell your doctor.</p><p>&nbsp;</p><p>Repeated use of the patches may make the medicine become less effective (you get used to it, or you may become more sensitive to pain), or you may become dependent on it.</p><p>&nbsp;</p><p>If you switch from a different painkiller to DUROGESIC or if you suddenly stop using DUROGESIC, you may notice withdrawal effects such as sickness, feeling sick, diarrhoea, anxiety or shivering. Tell your doctor if you notice any of these effects.</p><p>&nbsp;</p><p>There have been reports also of newborn infants experiencing withdrawal effects after their mothers have used DUROGESIC for a long time during pregnancy.</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Where you should keep the patches</p><p>Keep all patches (used and unused) out of the sight and reach of children.</p><p>Store in the original pouch to protect from light.</p><p>Store below 30&ordm;C, in the original unopened pouch.</p><p>&nbsp;</p><p>Store this medicine in a safe and secure place, where other people cannot access it. It can cause serious harm and be fatal to people who may take this medicine by accident, or intentionally when it has not been prescribed for them.</p><p>&nbsp;</p><p>How long to keep DUROGESIC for</p><p>Do not use DUROGESIC after the expiry date, which is stated on the carton and sachet. The expiry date refers to the last date of that month. If the patches are out of date, take them to your pharmacy.</p><p>&nbsp;</p><p>&nbsp;</p><p>How to dispose of used patches or patches you no longer use</p><p>A used or unused patch accidentally sticking to another person, especially a child, may be fatal.</p><p>&nbsp;</p><p>Used patches should be folded firmly in half so that the sticky side of the patch sticks to itself. Then they should be safely discarded by putting them back into the original sachet and stored out of sight and reach of other people, especially children, until safely disposed. Ask your pharmacist how to throw away medicines you no longer use.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What DUROGESIC contains</p><p><u>DUROGESIC 12 &micro;g/hour</u></p><p>The active substance in DUROGESIC is fentanyl. Each patch contains 2.1 mg of fentanyl, which delivers a dose of 12 micrograms/hour.</p><p><u>DUROGESIC 25 &micro;g/hour</u></p><p>The active substance in DUROGESIC is fentanyl. Each patch contains 4.2 mg of fentanyl, which delivers a dose of 25 micrograms/hour.</p><p><u>DUROGESIC 50 &micro;g/hour</u></p><p>The active substance in DUROGESIC is fentanyl. Each patch contains 8.4 mg of fentanyl, which delivers a dose of 50 micrograms/hour.</p><p><u>DUROGESIC 75 &micro;g/hour</u></p><p>The active substance in DUROGESIC is fentanyl. Each patch contains 12.6 mg of fentanyl, which delivers a dose of 75 micrograms/hour.</p><p><u>DUROGESIC 100 &micro;g/hour</u></p><p>The active substance in DUROGESIC is fentanyl. Each patch contains 16.8 mg of fentanyl, which delivers a dose of 100 micrograms/hour.</p><p>&nbsp;</p><p>Other ingredients in the patch are:</p><p><strong>&nbsp;</strong></p><p>Backing Layer:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Film, Polyester/Ethylene Vinyl Acetate Copolymer, Protective Liner:&nbsp; Film, Siliconized Polyester,</p><p>Drug Layer:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Polyacrylate Adhesive</p><p>&nbsp;</p><p>Inks (on backing):</p><p>The DUROGESIC 12 micrograms/hour patch also contains orange printing ink. The DUROGESIC 25 micrograms/hour patch also contains red printing ink.</p><p>The DUROGESIC 50 micrograms/hour patch also contains green printing ink. The DUROGESIC 75 micrograms/hour patch also contains blue printing ink. The DUROGESIC 100 micrograms/hour patch also contains grey printing ink.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What DUROGESIC looks like and contents of the pack

DUROGESIC 12 µg/hour
DUROGESIC is a translucent rectangular patch with rounded corners. Each patch is 5.25 cm2, and is marked with a border and “DUROGESIC 12 µg fentanyl/h” in orange printing ink.
DUROGESIC 25 µg/hour
DUROGESIC is a translucent rectangular patch with rounded corners. Each patch is 10.5 cm2, and is marked with a border and “DUROGESIC 25 µg fentanyl/h” in red printing ink.
DUROGESIC 50 µg/hour
DUROGESIC is a translucent rectangular patch with rounded corners. Each patch is 21.0 cm2, and is marked with a border and “DUROGESIC 50 µg fentanyl/h” in green printing ink.
DUROGESIC 75 µg/hour
DUROGESIC is a translucent rectangular patch with rounded corners. Each patch is 31.5 cm2, and is marked with a border and “DUROGESIC 75 µg fentanyl/h” in blue printing ink.
DUROGESIC 100 µg/hour
DUROGESIC is a translucent rectangular patch with rounded corners. Each patch is 42.0 cm2, and is marked with a border and “DUROGESIC 100 µg fentanyl/h” in grey printing ink.

The patches come in individually wrapped heat-sealed (acrylonitrile film or cyclic olefin copolymer) pouches, and come in cartons containing 3, 4, 5, 8, 10, 16, 20 or 30 patches.
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder:<br />&nbsp;</p><p>Janssen-Cilag NV</p><p>Antwerpseweg 15-17</p><p>B-2340 Beerse</p><p>Belgium</p><p>&nbsp;</p><p>&nbsp;</p><p>Manufacturer:</p><p>Janssen Pharmaceutica NV</p><p>Turnhoutseweg 30</p><p>B-2340 Beerse</p><p>Belgium</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>To contact us, go to </strong><strong>www.janssen.com/contact-us</strong><br />&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>This leaflet was last revised in March 2022</strong></p><p>&nbsp;</p><p>To reports any side effect(s):</p><p>Saudi Arabia:</p><p><strong>&nbsp;</strong></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-bookmark:_Hlk61811054'></span><span style='mso-element:field-begin;
mso-field-lock:yes'></span><span style='mso-bookmark:_Hlk61811054'><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_30" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='width:455.55pt;height:82.3pt;visibility:visible;
 mso-wrap-style:square;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001;v-text-anchor:top' filled="f">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:3.2pt;margin-right:0in;margin-bottom:
    0in;margin-left:35.5pt;margin-bottom:.0001pt;text-indent:-10.35pt;
    mso-list:l0 level1 lfo3;tab-stops:35.55pt;text-autospace:ideograph-numeric ideograph-other'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='letter-spacing:
    -.05pt'>The National</span> <span style='letter-spacing:-.05pt'>Pharmacovigilance
    Centre (NPC):</span><o:p></o:p></p>
    <p class=MsoNormal style='margin-left:35.5pt;text-indent:-10.35pt;
    line-height:12.85pt;mso-line-height-rule:exactly;mso-list:l2 level1 lfo2;
    tab-stops:35.55pt;text-autospace:ideograph-numeric ideograph-other'><![if !supportLists]><span
    style='font-family:"Calibri",sans-serif;mso-fareast-font-family:Calibri'><span
    style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span>Fax: +966-11-205-7662<o:p></o:p></p>
    <p class=MsoNormal style='margin-left:35.5pt;text-indent:-10.35pt;
    line-height:12.85pt;mso-line-height-rule:exactly;mso-list:l2 level1 lfo2;
    tab-stops:35.55pt;text-autospace:ideograph-numeric ideograph-other'><![if !supportLists]><span
    style='font-family:"Calibri",sans-serif;mso-fareast-font-family:Calibri'><span
    style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='letter-spacing:
    -.05pt'>SFDA Call Center: 19999</span><o:p></o:p></p>
    <p class=MsoNormal style='margin-left:35.5pt;text-indent:-10.35pt;
    line-height:13.0pt;mso-line-height-rule:exactly;mso-list:l2 level1 lfo2;
    tab-stops:35.55pt;text-autospace:ideograph-numeric ideograph-other'><![if !supportLists]><span
    lang=IT style='font-family:"Calibri",sans-serif;mso-fareast-font-family:
    Calibri;mso-ansi-language:IT'><span style='mso-list:Ignore'>-<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span lang=IT style='letter-spacing:-.05pt;mso-ansi-language:
    IT'>E-mail:</span><span lang=IT style='letter-spacing:.05pt;mso-ansi-language:
    IT'> </span><a href="mailto:npc.drug@sfda.gov.sa"><span lang=IT
    style='color:#0000FD;letter-spacing:-.05pt;mso-ansi-language:IT'>npc.drug@sfda.gov.sa</span></a><span
    lang=IT style='mso-ansi-language:IT'><o:p></o:p></span></p>
    <p class=MsoNormal style='margin-left:35.5pt;text-indent:-10.35pt;
    line-height:13.3pt;mso-line-height-rule:exactly;mso-list:l2 level1 lfo2;
    tab-stops:35.55pt;text-autospace:ideograph-numeric ideograph-other'><![if !supportLists]><span
    style='font-family:"Calibri",sans-serif;mso-fareast-font-family:Calibri'><span
    style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span>Website: <a
    href="https://ade.sfda.gov.sa/"><span style='color:#0000FD;letter-spacing:
    -.05pt'>https://ade.sfda.gov.sa/</span></a><o:p></o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="612" height="114" alt="Text Box: •	The National Pharmacovigilance Centre (NPC):
-	Fax: +966-11-205-7662
-	SFDA Call Center: 19999
-	E-mail: npc.drug@sfda.gov.sa
-	Website: https://ade.sfda.gov.sa/
" src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-bookmark:_Hlk61811054'></span><v:shape id="_x0000_i1025" type="#_x0000_t75"
 style='width:455.55pt;height:82.3pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-bookmark:_Hlk61811054'><span style='mso-element:
field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Other GCC States:</strong></p><p>&ndash; Please contact the relevant competent authority.</p><p>&nbsp;</p><p>&nbsp;</p><p>Council of arab health ministers</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:649px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>THIS IS A MEDICAMENT</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Follow strictly the doctor&#39;s prescription, the method of use and the instructions of the pharmacist who sold the medicament. The doctor and the pharmacist are the experts in medicines, their benefits and risks.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not by yourself interrupt the period of treatment prescribed.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not repeat the same prescription without consulting your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep all medicaments out of the reach of children</p></td></tr></tbody></table><p>Council of Arab Health Ministers</p><p>Union of Arab Pharmacists</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>This patient information leaflet is approved by the Saudi Food and Drug Administration </strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in March 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">اسم الدواء هو دوروجيسيك</p><p dir="RTL">&nbsp;</p><p dir="RTL">تساعدك اللاصقات على تخفيف الآلام الشديدة والمستمرة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للبالغين الذين يلزمهم علاج آلام مستمرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للأطفال فوق سن السنتين الذين يستخدمون بالفعل دواءً أفيونيًا أو يلزمهم علاج آلام مستمرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي دوروجيسيك على مادة فعالة تسمى فينتانيل. وهو ينتمي إلى مجموعة من المسكنات القوية تسمى المسكنات الأفيونية.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية لمادة فينتانيل أو أي من المكونات الأخرى في هذا الدواء (مدرجة في القسم 6)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ألام تدوم لفترات قصيرة؛ مثل الآلام المفاجئة أو الآلام الناتجة عن الخضوع لعملية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من صعوبة في التنفس، مع تنفس بطيء أو ضحل</p><p dir="RTL">تجنّب استخدام هذا الدواء إذا كانت أي من الحالات المذكورة أعلاه تنطبق عليك أو على طفلك. وإذا لم تكن متأكدًا، فاستشر الطبيب أو الصيدلاني قبل استخدام دوروجيسيك.</p><p>&nbsp;</p><p>تحذيرات واحتياطات</p><p dir="RTL"><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  left:0;text-align:left;margin-left:65.3pt;margin-top:13pt;width:464.9pt;
  height:93.4pt;z-index:-15703040;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page' filled="f"
  strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText dir=RTL style='margin-top:.95pt;margin-right:23.35pt;
     margin-bottom:0in;margin-left:10.9pt;margin-bottom:.0001pt;text-indent:
     -.25in;mso-list:l1 level1 lfo1;tab-stops:23.35pt 23.4pt'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA>يمكن
     أن يتسبب ديوروجيسيك في ظهور آثار جانبية مهددة للحياة لدى الأشخاص الذين لا
     يستخدمون بالفعل الأدوية الأفيونية الموصوفة لهم بانتظام.</span><span
     dir=LTR><o:p></o:p></span></p>
     <p class=MsoBodyText dir=RTL style='margin-top:0in;margin-right:23.35pt;
     margin-bottom:0in;margin-left:12.6pt;margin-bottom:.0001pt;text-indent:
     -.25in;mso-list:l1 level1 lfo1;tab-stops:23.35pt 23.4pt'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA>ديوروجيسيك
     هو دواء قد يكون مهددًا لحياة الأطفال، حتى في حال كانت اللاصقات هي النوع
     المُستخدم. ضع في اعتبارك أن اللاصقة (غير المستخدمة أو المستخدمة) قد تجذب
     انتباه الطفل، وإذا التصقت بجلده أو وضعها في فمه، فقد يتسبب ذلك في التعرض
     لأضرار مهددة للحياة.</span><span dir=LTR><o:p></o:p></span></p>
     <p class=MsoBodyText dir=RTL style='margin-top:0in;margin-right:23.35pt;
     margin-bottom:0in;margin-left:13.95pt;margin-bottom:.0001pt;text-indent:
     -.25in;mso-list:l1 level1 lfo1;tab-stops:23.35pt 23.4pt'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA>خزّن
     هذا الدواء في بيئة آمنة بعيدًا عن متناول الآخرين - انظر القسم </span><span
     dir=LTR></span><span dir=LTR style='mso-bidi-language:#007F'><span
     dir=LTR></span>5</span><span dir=RTL></span><span lang=AR-SA><span
     dir=RTL></span> لمزيد من المعلومات.</span><span dir=LTR><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="623" height="129" alt="Text Box: •	يمكن أن يتسبب ديوروجيسيك في ظهور آثار جانبية مهددة للحياة لدى الأشخاص الذين لا يستخدمون بالفعل الأدوية الأفيونية الموصوفة لهم بانتظام.
•	ديوروجيسيك هو دواء قد يكون مهددًا لحياة الأطفال، حتى في حال كانت اللاصقات هي النوع المُستخدم. ضع في اعتبارك أن اللاصقة (غير المستخدمة أو المستخدمة) قد تجذب انتباه الطفل، وإذا التصقت بجلده أو وضعها في فمه، فقد يتسبب ذلك في التعرض لأضرار مهددة للحياة.
•	خزّن هذا الدواء في بيئة آمنة بعيدًا عن متناول الآخرين - انظر القسم 5 لمزيد من المعلومات.
" src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>لصق اللاصقة على جسم شخص آخر</strong></p><p dir="RTL">ينبغي استخدام اللاصقة على جلد الشخص الذي وُصِفت له فقط. لقد وصلتنا إبلاغات عن حالات التصقت فيها اللاصقات بغير قصد بأحد أفراد العائلة عند حدوث اتصال جسدي مباشر أو عند مشاركة السرير نفسه مع شخص يضع اللاصقة. قد يتسبب التصاق اللاصقة دون قصد بشخص آخر (وبخاصة إذا كان طفلًا) في مرور الدواء عبر جلده مسببًا له آثارًا جانبيةً خطيرة قد تودي بحياته؛ مثل الصعوبة في التنفس، مع تنفس بطيء أو ضحل. في حال التصقت اللاصقة بجلد شخص آخر، أزلها عنه فورًا واطلب له عناية طبية.</p><p dir="RTL">&nbsp;</p><p>اتخاذ الحيطة عند استخدام دوروجيسيك</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">استشر الطبيب أو الصيدلاني لديك قبل استخدام هذا الدواء إذا كان ينطبق عليك أي مما يلي - وقد يحتاج طبيبك إلى إجراء المزيد من الفحوصات عليك في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق أن عانيت من أي مشكلات في رئتيك أو في التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق أن عانيت من مشكلات في القلب، أو الكبد، أو الكليتين، أو انخفاض ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق أن عانيت من ورم دماغي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق أن عانيت من نوبات صداع مستمرة أو عانيت من إصابة في رأسك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مُسنًّا - قد تكون أكثر حساسية تجاه التأثيرات الناتجة عن هذا الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت تعاني من حالة تعرف باسم &quot;الوهن العضلي الوبيل&quot;، وهي حالة تتسبب في ضعف العضلات وإرهاقها بسهولة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتعاطى أنت أو أحد أفراد عائلتك المواد الكحولية أو الأدوية الموصوفة أو المخدرات المحظورة قانونًا أو مدمنًا لها (&quot;الإدمان&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مدخنًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق أن عانيت من مشكلات في حالتك المزاجية (اكتئاب، أو قلق، أو اضطراب في الشخصية) أو ذهبت إلى طبيب نفسي للتعافي من أي أمراض عقلية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان أي مما ذُكِرَ أعلاه ينطبق على حالتك (أو لم تكن متأكدًا من ذلك)، فاستشر الطبيب أو الصيدلاني لديك قبل استخدام دوروجيسيك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تعاني من مشكلات في التنفس أثناء النوم عند استخدام هذه اللاصقة. يمكن أن تتسبب المواد الأفيونية؛ مثل دوروجيسيك، في حدوث اضطرابات التنفس المرتبطة بالنوم؛ مثل انقطاع النفس النومي (توقف التنفس أثناء النوم) ونقص تأكسج الدم المرتبط بالنوم (انخفاض مستوى الأكسجين في الدم). أخبر طبيبك إذا لاحظت أنت أو شريكك أو مقدم الرعاية الخاص بك أيًّا مما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توقف التنفس أثناء النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاستيقاظ ليلًا نتيجة الشعور بضيق في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على النوم لفترات طويلة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور الشديد بالنعاس خلال اليوم. قد يقرر طبيبك تغيير الجرعة التي تتلقاها.</p><p dir="RTL">&nbsp;</p><p>أخبر طبيبك إذا كنت تلاحظ أي تغيرات في الآلام التي تشعر بها عند استخدام هذه اللاصقة. إذا كنت تشعر بأيٍّ مما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أن اللاصقة لم تعد تخفف من ألمك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أن الألم يزيد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أن هناك تغيرات في الألم الذي تشعر به (كأن تشعر بالألم في جزء آخر من جسمك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أن الألم يظهر من أقل لمسة لجسمك على نحوٍ لم تكن تتوقعه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تجنّب تغيير الجرعة التي تتلقاها بنفسك. وحده طبيبك من يقرر تغيير الجرعة أو الدواء الذي تتلقاه.</p><p>الآثار الجانبية ودوروجيسيك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتسبب دوروجيسيك في شعورك بالنعاس غير المعتاد، وجعل تنفسك بطيئًا أكثر أو ضحلًا أكثر. نادرًا جدًا ما تكون هذه المشكلات المتعلقة بالتنفس مهددة للحياة أو حتى مميتة، وخاصة لدى الأشخاص الذين لم يستخدموا مسكنات ألم أفيونية قوية من قبل (مثل الدوروجيسيك أو المورفين). إذا لاحظت أنت، أو شريكك، أو مقدم الرعاية الصحية الخاص بك أن الشخص الذي يضع اللاصقة يشعر بالنعاس غير المعتاد، ويعاني من تنفس بطيء أو ضحل، فنفّذ ما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزل اللاصقة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتصل بالطبيب، أو توجه إلى أقرب مستشفى على الفور.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اطلب من الشخص التحرك وعدم البقاء ساكنًا وحاول فتح حديث معه قدر الإمكان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصبت بالحمى أثناء استخدام دوروجيسيك، فأخبر طبيبك - قد يتسبب هذا في زيادة كمية الدواء التي تتسرب عبر جلدك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتسبب دوروجيسيك في الإصابة بالإمساك، لذا تحدث مع طبيبك أو الصيدلي لديك لمعرفة كيفية تجنب الإصابة بالإمساك أو التخلص منه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتسبب الاستخدام المتكرر للَّاصقات على المدى الطويل في تقليل فعالية الدواء (يعتاد جسمك عليه، أو ربما تصبح أكثر حساسية تجاه الشعور بالألم)، في عدم قدرتك على الاستغناء عنه بعد ذلك. قد تساعدك زيادة جرعة اللاصقات على تخفيف ألمك لفترة أطول من الوقت، ولكن قد تسبب الضرر لك أيضًا. إذا لاحظت أن دواءك أصبح أقل فعالية، فتحدث مع طبيبك. سوف يحدد الطبيب ما إذا كان من الأفضل لك زيادة جرعة دوروجيسيك التي تتلقاها أو تقليلها تدريجيًا. وفي حال ساورك القلق أيضًا من ألا يعود بإمكانك الاستغناء عن هذا الدواء، فاستشر طبيبك بخصوص هذا الأمر.</p><p dir="RTL">انظر القسم 4 للاطلاع على القائمة الكاملة للآثار الجانبية المحتملة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عند وضع اللاصقة، تجنّب تعريضها للحرارة المباشرة؛ مثل وسائد التدفئة، أو البطانيات الكهربائية، أو الأسرة المائية الدافئة، أو مصابيح التدفئة أو تسمير البشرة. امتنع عن حمام الشمس، أو الاستحمام بالماء الساخن لفترات طويلة، أو حمامات البخار، أو حمامات سبا الدوامية الساخنة. إذا فعلت ذلك، فقد تتسبب في زيادة جرعة الدواء التي تتلقاها من اللاصقة.</p><p dir="RTL">&nbsp;</p><p>أعراض الانسحاب عند التوقف عن استخدام دوروجيسيك</p><p dir="RTL">تجنب التوقف عن استخدام هذا الدواء بصورة مفاجئة. قد تظهر عليك أعراض انسحاب؛ مثل الأرق، أو صعوبة النوم، أو تهيج الجلد، الانفعال، أو القلق، أو الشعور بضربات القلب (خفقان القلب)، أو ارتفاع ضغط الدم، أو الشعور بالتعب، أو الإسهال، أو فقدان الشهية، أو الارتجاف، أو الشعور بالقشعريرة، أو التعرق. إذا كنت ترغب في التوقف عن استخدام هذا الدواء، فتحدث مع طبيبك أولًا. سوف يُخبرك طبيبك بالطريقة المناسبة للقيام بذلك، وعادة ما يكون ذلك بتقليل الجرعة تدريجيًا للمحافظة على أعراض الانسحاب المزعجة في أدنى مستوى لها.</p><p dir="RTL">&nbsp;</p><p>الأدوية الأخرى ودوروجيسيك</p><p dir="RTL">أخبر طبيبك أو الصيدلاني إذا كنت تحصل على أدوية أخرى أو حصلت على أي أدوية أخرى مؤخرًا أو قد تحصل على أي أدوية أخرى. يتضمن ذلك الأدوية التي تشتريها دون وصفة طبية أو الأعشاب الطبية. ينبغي لك أيضًا إخبار الصيدلي أنك تستخدم دوروجيسيك إذا كنت تشتري أي أدوية من الصيدلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يكون طبيبك على علم بالأدوية التي تكون آمنة عند تلقيها مع دوروجيسيك. قد يلزم وضعك تحت الملاحظة عن كثب إذا كنت تتلقى بعض أنواع الأدوية المذكورة أدناه أو إذا توقفت عن تلقي بعض أنواع الأدوية المذكورة أدناه، لأن ذلك قد يؤثر في مفعول دوروجيسيك الذي تحتاجه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وينبغي على وجه الخصوص إخبار طبيبك إذا كنت تتلقى أيًّا مما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى لتخفيف الألم؛ مثل المسكنات الأفيونية الأخرى (على سبيل المثال: بيوبرينورفين، أو نالبوفين، أو بنتازوسين) وبعض مسكنات الآلام العصبية (على سبيل المثال: غابابنتين وبريغابالين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية منوّمة (على سبيل المثال: تيمازيبام، أو زاليبلون، أو زولبيديم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تساعدك على الاسترخاء (مهدئات، مثل ألبرازولام، أو كلونازيبام، أو ديازيبام، أو هيدروكسيزين، أو لورازيبام) وأدوية للأمراض العقلية (مضادات الذهان؛ مثل أريبيبرازول، أو هالوبيريدول، أو أولانزابين، أو ريسبيريدون، أو فينوثيازين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لإرخاء عضلات جسمك (مثل سيكلوبينزابرين، أو ديازيبام).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُعرف بعض الأدوية المستخدمة لعلاج الاكتئاب باسم مثبطات إعادة امتصاص السيروتونين الانتقائية (SSRIs) أو مثبطات استرداد السيروتونين والنورابينفرين (SNRIs) (مثل سيتالوبرام، أو دولوكسيتين، أو إسيتالوبرام، أو فلوكسيتين، أو فلوفوكسامين، أو باروكسيتين، أو سيرترالين، أو فينلافاكسين). - انظر أدناه لمزيد من المعلومات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المستخدمة لعلاج الاكتئاب أو مرض باركنسون المعروفة باسم مضادات الاكتئاب (MAOIs) (مثل إيزوكاربوكسازيد، أو فينيلزين، أو سيليجيلين، أو ترانيلسيبرومين) وينبغي تجنّب تلقي دوروجيسيك قبل مرور 14 يومًا من تاريخ التوقف عن تلقي هذه الأدوية. - انظر أدناه لمزيد من المعلومات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض مضادات الهيستامين، وبخاصة تلك التي تجعلك تشعر بالنعاس (مثل كلورفينيرامين، أو كليماستين، أو سيبروهيبتادين، أو ديفينهيدرامين، أو هيدروكسيزين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض المضادات الحيوية المستخدمة لعلاج الالتهابات (مثل إريثروميسين أو كلاريثروميسين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تُستخدم لعلاج الالتهابات الفطرية (مثل إتراكونازول، أو كيتوكونازول، أو فلوكونازول، أو فوريكونازول).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تُستخدم لعلاج عدوى فيروس نقص المناعة البشرية (HIV) (مثل ريتونافير).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تُستخدم لعلاج عدم انتظام ضربات القلب (مثل أميودارون، أو ديلتيازيم، أو فيراباميل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تُستخدم لعلاج السل (مثل ريفامبيسين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المستخدمة لعلاج الصرع (مثل كاربامازيبين، أو الفينوباربيتال، أو الفينيتوين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المستخدمة لعلاج الغثيان أو دوار الحركة (مثل الفينوثيازين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المستخدمة لعلاج حرقة المعدة أو قرح المعدة (مثل سيميتيدين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المستخدمة لعلاج الذبحة الصدرية (ألم في الصدر) أو ارتفاع ضغط الدم (مثل نيكارديبين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المستخدمة لعلاج سرطان الدم (مثل إديلاليسيب).</p><p dir="RTL">&nbsp;</p><p>دوروجيسيك مع مضادات الاكتئاب</p><p dir="RTL">تزداد خطورة الآثار الجانبية إذا كنت تتلقى أدوية؛ مثل بعض مضادات الاكتئاب. قد يتفاعل دوروجيسيك مع هذه الأدوية وقد تواجه تغيرات في الحالة العقلية؛ مثل الشعور بالغضب أو التوهم برؤية أشياء غير موجودة أو الشعور بها أو سماعها أو شمها (الهلوسة) وتأثيرات أخرى؛ مثل تغير ضغط الدم وسرعة ضربات القلب وارتفاع درجة حرارة الجسم، وردود الأفعال المفرطة، وانعدام التنسيق، وتصلب العضلات، والغثيان، والقيء، والإسهال (قد تكون هذه علامات لمتلازمة السيروتونين). في حال استخدامهما معًا، قد يرغب طبيبك في وضعك تحت الملاحظة عن كثب لرصد هذه الآثار الجانبية على وجه الخصوص عند بدء العلاج أو عند تغيير جرعة الدواء التي تتلقاها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الاستخدام مع مثبطات الجهاز العصبي المركزي؛ بما في ذلك المواد الكحولية وبعض العقاقير المخدرة يؤدي استخدام دوروجيسيك مع الأدوية المهدئة؛ مثل البنزوديازيبينات أو العقاقير ذات الصلة إلى زيادة خطر النعاس، وصعوبة التنفس (تثبيط الجهاز التنفسي)، والغيبوبة، وقد تكون مهددة للحياة. لهذا السبب، ينبغي عدم استخدامه مع أدوية أخرى إلا إذا كانت خيارات العلاج الأخرى غير ممكنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وفي حال وصف طبيبك دوروجيسيك مع أدوية مهدئة، يجب عليه أن يحدد جرعة العلاج ومدة استخدامه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الرجاء إخبار طبيبك بجميع الأدوية المهدئة التي تتناولها، والالتزام بتوصياته جيدًا. وقد يفيدك أن تطلب من أصدقائك أو أقاربك أن يكونوا على دراية بالعلامات والأعراض المذكورة أعلاه. اتصل بطبيبك عند ظهور مثل هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تجنب شرب أي مواد كحولية طوال فترة استخدام دوروجيسيك دون استشارة طبيبك.</p><p dir="RTL">&nbsp;</p><p>العمليات</p><p dir="RTL">إذا كنت تظن أنه سوف يتم تخديرك، فأخبر طبيبك أو طبيب الأسنان الذي تتابع معه أنك تستخدم دوروجيسيك.</p><p dir="RTL">&nbsp;</p><p>الحمل والرضاعة الطبيعية</p><p dir="RTL">إذا كنتِ حاملًا أو مرضعة، أو تعتقدين أنك حامل، أو تخططين للإنجاب، فعليكِ استشارة الطبيب أو الصيدلي قبل استخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عدم استخدام دوروجيسيك طوال فترة الحمل دون استشارة طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عدم استخدام دوروجيسيك أثناء الولادة؛ لأنه قد يضر بالتنفس لدى المولود.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُمكن أن يتسبب الاستخدام الممتد لدوروجيسيك أثناء الحمل في ظهور أعراض انسحاب (مثل البكاء الشديد، والعصبية، والنوبات، وسوء التغذية والإسهال) على مولودك، وقد تكون هذه الأعراض مهددة للحياة إذا لم يتم اكتشافها وعلاجها. تحدثي مع طبيبكِ على الفور إذا كنتِ ترين أن طفلك ربما يعاني من أعراض الانسحاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تجنبي استخدام دوروجيسيك إذا كنت ترضعين طفلك طبيعيًا. ينبغي لك التوقف عن إرضاع طفلك طبيعيًا لمدة ثلاثة أيام من إزالة لاصقة دوروجيسيك عن جسمكِ. وذلك لأن الدواء قد ينتقل إلى الطفل من خلال لبن الأم.</p><p dir="RTL">&nbsp;</p><p>القيادة واستخدام الآلات</p><p dir="RTL">قد يؤثر دوروجيسيك في قدرتك على قيادة السيارة واستخدام الآلات أو الأدوات لأنه قد يُشعرك بالنعاس أو بالدوار. إذا حدث ذلك فتجنب قيادة السيارة أو استخدام أي أدوات أو آلات. تجنب القيادة أثناء استخدام هذا الدواء لحين معرفة تأثيره عليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تكن متأكدًا من أن قيادتك أثناء فترة تلقي هذا الدواء تعد آمنة، فاستشر طبيبك أو الصيدلاني لديك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم هذا الدواء دائمًا كما أخبرك الطبيب أو الصيدلاني بالضبط. وينبغي لك استشارة الطبيب أو الصيدلاني في حال عدم التأكد من طريقة الاستعمال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يقرر طبيبك تركيز دوروجيسيك الأنسب لك، مع مراعاة شدة الألم، وحالتك العامة ونوع علاج الألم الذي تلقيته حتى الآن.</p><p dir="RTL">&nbsp;</p><p>استخدام اللاصقات وتغييرها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحتوي كل لاصقة على جرعة دواء تكفي لمدة <strong>3</strong> أيام (<strong>72</strong> ساعة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي لك تغيير اللاصقة كل ثلاثة أيام، ما لم يُعطك الطبيب تعليمات أخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احرص دائمًا على إزالة اللاصقة القديمة قبل استخدام أخرى جديدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احرص دائمًا على تغيير اللاصقة في الوقت نفسه من اليوم كل 3 أيام (72 ساعة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم أكثر من لاصقة، فغيِّر كل اللاصقات في الوقت نفسه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أنشئ ملاحظة باليوم والساعة اللذين تضع فيهما اللاصقة؛ لتذكيرك بالوقت الذي يلزمك تغيير اللاصقة فيه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوف يعرض لك الجدول أدناه موعد تغيير اللاصقة التي تضعها.</p><p dir="RTL">&nbsp;</p><p>ضع اللاصقة يوم&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; غيِّر اللاصقة يوم</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;الإثنين&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخميس</p><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="image2.png" o:spid="_x0000_s1034" type="#_x0000_t75" style='position:absolute;
 left:0;text-align:left;margin-left:238.4pt;margin-top:3.3pt;width:21.5pt;
 height:7.95pt;z-index:-16797184;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="29" height="11" src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" />الثلاثاء&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجمعة</p><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="image3.png" o:spid="_x0000_s1033" type="#_x0000_t75" style='position:absolute;
 left:0;text-align:left;margin-left:238.4pt;margin-top:3.25pt;width:21.5pt;
 height:7.85pt;z-index:-16796672;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="29" height="11" src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gif" />الأربعاء&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السبت</p><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="image4.png" o:spid="_x0000_s1032" type="#_x0000_t75" style='position:absolute;
 left:0;text-align:left;margin-left:238.4pt;margin-top:3.6pt;width:21.5pt;
 height:7.95pt;z-index:-16796160;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image007.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="29" height="11" src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image008.gif" />الخميس&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأحد</p><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="image5.png" o:spid="_x0000_s1031" type="#_x0000_t75" style='position:absolute;
 left:0;text-align:left;margin-left:238.4pt;margin-top:4.05pt;width:21.5pt;
 height:7.85pt;z-index:-16795648;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image009.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="29" height="11" src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image010.gif" />الجمعة&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإثنين</p><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="_x0000_s1030" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:238.4pt;margin-top:3.75pt;width:21.5pt;height:7.95pt;
 z-index:-16795136;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image007.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="29" height="11" src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image011.gif" />السبت&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الثلاثاء</p><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="_x0000_s1029" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:238.4pt;margin-top:3.35pt;width:21.5pt;height:7.95pt;
 z-index:-16794624;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image012.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="29" height="11" src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image013.gif" />الأحد&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأربعاء</p><p dir="RTL">&nbsp;</p><p>موضع استخدام اللاصقة لدى البالغين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضع اللاصقة على منطقة مستوية من الجزء العلوي لجسمك أو من ذراعك (تجنب المفاصل).</p><p dir="RTL">&nbsp;</p><p>للأطفال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احرص دائمًا على وضع اللاصقة أعلى الظهر كي لا يتمكن الطفل من الوصول إليها أو إزالتها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألق نظرة على اللاصقة من حين لآخر للتأكد من أنها مُلصقة جيدًا على الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من المهم الانتباه للطفل حرصًا على ألا يزيل اللاصقة ويضعها في فمه؛ لأن هذا قد يعرض الطفل لخطر مهدد للحياة أو مميت.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; راقب طفلك عن كثب جيدًا لمدة 48 ساعة بعد:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; وضع اللاصقة الأولى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; وضع لاصقة تحتوي على جرعة أكبر من الدواء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تستغرق اللاصقة بعض الوقت كي تحقق أقصى تأثير لها. لذلك، قد يحتاج طفلك إلى استخدام مسكنات أخرى إلى جانب اللاصقات إلى أن تصبح اللاصقات فعالة. سوف يتحدث معك طبيبك حول هذا.</p><p dir="RTL">&nbsp;</p><p>للأطفال والمراهقين:</p><p dir="RTL">لا تضع اللاصقة على أيٍّ مما يلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; على المكان نفسه مرتين متتاليتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المناطق التي تحركها كثيرًا من جسمك (المفاصل)، أو الأماكن التي يكون الجلد فيها ملتهبًا أو مجروحًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأماكن كثيفة الشعر. في حال وجود شعر على الجلد، تجنب إزالته بالشفرة (لأن الإزالة بالشفرة تهيج البشرة). بدلًا من ذلك، قص الشعر بحيث يكون قريبًا من البشرة إلى أقصى درجة ممكنة.</p><p dir="RTL">&nbsp;</p><p>وضع لاصقة</p><p dir="RTL">الخطوة <strong>1</strong>: تجهيز موضع اللصق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احرص على إبقاء موضع اللصق جافًا تمامًا، ونظيفًا، وباردًا قبل وضع اللاصقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بحاجة إلى تنظيف موضع اللصق، فاستخدم ماءً باردًا فقط</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنب استخدام الصابون أو غيره من المنظفات، أو الكريمات، أو المرطبات، أو الزيوت، أو مساحيق التجميل قبل وضع اللاصقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنب وضع اللاصقة بعد الاستحمام بماء ساخن مباشرةً</p><p dir="RTL">&nbsp;</p><p>الخطوة 2: فتح الكيس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توضع كل لاصقة في كيس خاص بها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; افتح الكيس عن طريق تمزيقه أو قصه من الموضع المخصص للفتح الموضح بالسهم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مزق طرف الكيس أو قصه تمامًا بلطف (إذا كنت تستخدم مقصًا، فقص الكيس من موضع قريب لطرف الكيس المغلق لتجنب إتلاف اللاصقة)</p><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="image6.png" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:145.5pt;
 height:67.5pt;flip:x;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image014.png"
  o:title=""/>
</v:shape><![endif]--><img width="194" height="90" src="data:image/png;base64,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" /></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمسك الكيس المفتوح من كلا الجانبين لفصله عن بعضه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخرج اللاصقة من الكيس واستخدمها على الفور</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتفظ بالكيس الفارغ للتخلص من اللاصقة المستعملة فيه لاحقًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُستخدم اللاصقة مرة واحدة فقط</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احرص على إخراج اللاصقة من الكيس فقط عندما تكون جاهزًا لوضعها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; افحص اللاصقة للتأكد من عدم تلفها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم اللاصقة إذا كانت منقسمة أو مقصوصة أو تبدو تالفة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنب تقسيم اللاصقة أو قصها</p><p dir="RTL">&nbsp;</p><p>الخطوة 3: نزع غلاف اللاصقة وضغطها على الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احرص على ارتداء ملابس واسعة فوق اللاصقة، وعدم وضعها تحت سوار ضيق أو مطاطي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انزع النصف الأول من الغلاف البلاستيكي اللامع من منتصف اللاصقة. حاول تجنب لمس الجزء اللاصق من اللاصقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضغط هذا الجزء اللاصق من اللاصقة على الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزل النصف الثاني من الغلاف واضغط اللاصقة كلها على الجلد براحة يدك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أبق يدك على اللاصقة لمدة 30 ثانية على الأقل. تأكد من التصاقها جيدًا، وبخاصة أطرافها.</p><p dir="RTL">&nbsp;</p><p>الخطوة 4: إزالة اللاصقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اطوِ اللاصقة من المنتصف جيدًا فور إزالتها لكي يلتصق الجزء اللاصق ببعضه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعدها إلى كيسها الأصلي وتخلص من الكيس بحسب تعليمات الصيدلاني لديك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احرص على إبقاء اللاصقات المستعملة بعيدًا عن متناول الأطفال وأنظارهم - لأن اللاصقات المستعملة قد تحتوي على قدر من الدواء يكفي للإضرار بالأطفال، بل وقد يكون مميتًا</p><p dir="RTL">&nbsp;</p><p>الخطوة 5: الغسيل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احرص دائمًا على غسل يديك بماء نظيف فقط بعد استخدام اللاصقة</p><p>&nbsp;</p><p>مزيد من المعلومات حول استخدام دوروجيسيك</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">الأنشطة اليومية أثناء استخدام اللاصقات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمتاز اللاصقات بكونها مضادة للماء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُمكنك الاستحمام أثناء وضع اللاصقة، ولكن تجنب فرك اللاصقة نفسها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا وافق طبيبك، فيُمكنك ممارسة التمارين أو لعب الألعاب الرياضية أثناء ارتداء اللاصقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُمكنك أيضًا السباحة أثناء استخدام اللاصقة، ولكن مع مراعاة ما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; تجنّب استخدام حمامات سبا الدوامية الساخنة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; تجنب ارتداء سوار ضيق أو مطاطي على اللاصقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أثناء وضع اللاصقة، تجنّب تعريضها للحرارة المباشرة؛ مثل وسائد التدفئة، أو البطانيات الكهربائية، أو الأسرة المائية الدافئة، أو مصابيح التدفئة أو تسمير البشرة. تجنّب حمامات الشمس، أو الاستحمام بالماء الساخن لفترات طويلة، أو حمامات البخار. إذا فعلت ذلك، فقد تتسبب في زيادة جرعة الدواء التي تتلقاها من اللاصقة.</p><p dir="RTL">&nbsp;</p><p>ما المدة التي ستستغرقها اللاصقة لتكون فعالة؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تستغرق اللاصقة الأولى التي تضعها بعض الوقت كي تحقق أقصى تأثير لها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يصف لك الطبيب مسكنات أخرى بالإضافة إليها في اليوم الأول أو ما إلى ذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد هذا، من المفترض أن تساعدك اللاصقة في تخفيف الألم باستمرار كي تتمكن من التوقف عن تلقي المسكنات. وقد يستمر طبيبك في وصف المسكنات لك من حين لآخر.</p><p dir="RTL">&nbsp;</p><p>إلى متى ستستخدم اللاصقات؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُستخدم لاصقات دوروجيسيك لعلاج الآلام طويلة الأمد. سوف يتمكن طبيبك من إخبارك بالمدة المتوقعة لاستخدامك اللاصقات</p><p dir="RTL">&nbsp;</p><p>زيادة شدة الألم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا زادت شدة ألمك فجأة بعد وضع آخر لاصقة محددة لك، فينبغي لك فحص اللاصقة. إذا لم تكن مُلصقة جيدًا أو سقطت، فينبغي لك استبدالها (انظر أيضًا قسم &quot;سقوط اللاصقة&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا زادت شدة ألمك بمرور الوقت أثناء استخدامك لهذه اللاصقات، فقد يجرب طبيبك لاصقة أكثر تركيزًا، أو يصف لك مسكنات إضافية (وقد يفعل كليهما).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت زيادة تركيز اللاصقة بلا فائدة، فقد يقرر طبيبك التوقف عن استخدام اللاصقات.</p><p dir="RTL">&nbsp;</p><p>استخدام لاصقات أكثر من اللازم أو استخدام لاصقات بتركيز غير مناسب</p><p dir="RTL">إذا استخدمت لاصقات أكثر من اللازم أو استخدمت لاصقات بتركيز غير مناسب، فانزع اللاصقات عنك واتصل بطبيبك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتضمن أعراض تلقي جرعة زائدة المعاناة من صعوبة في التنفس، أو التنفس الضحل، أو الإرهاق، أو الشعور الزائد بالنعاس، أو عدم القدرة على التفكير بوضوح، أو الشعور بالإغماء، أو الدوخة، أو الاضطراب أثناء المشي أو عدم القدرة على التحدث بشكل طبيعي.</p><p dir="RTL">&nbsp;</p><p>نسيان تغيير اللاصقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا نسيت تغيير اللاصقة، فغيّرها فور تذكّرك وأنشئ ملاحظة باليوم والساعة اللذين غيرتها فيهما. غيِّر اللاصقة مرة أخرى بعد <strong>3</strong> أيام (<strong>72</strong> ساعة) كالمعتاد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تأخرت كثيرًا على موعد تغيير اللاصقة، فتحدث مع طبيبك؛ لأنك قد تحتاج إلى تلقي بعض المسكنات الإضافية وتجنّب وضع لاصقة إضافية.</p><p dir="RTL">&nbsp;</p><p>سقوط اللاصقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سقطت اللاصقة قبل حلول موعد تغييرها، فألصق أخرى جديدة فورًا وأنشئ ملاحظة باليوم والساعة اللذين غيرتها فيهما. ضع اللاصقة على منطقة أخرى من:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجزء العلوي من جسمك أو ذراعك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعلى ظهر طفلك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك بما حدث واترك اللاصقة لمدة <strong>3</strong> أيام (<strong>72</strong> ساعة) أخرى أو حسب توجيهات طبيبك، قبل تغيير اللاصقة الجديدة كالمعتاد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا استمرت اللاصقات في السقوط عن جسمك، فتحدث مع طبيبك، أو الصيدلاني، أو الممرضة لديك.</p><p>&nbsp;</p><p>الرغبة في التوقف عن استخدام اللاصقات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنب التوقف عن استخدام هذا الدواء بصورة مفاجئة. إذا كنت ترغب في التوقف عن استخدام هذا الدواء، فتحدث مع طبيبك أولًا. سوف يُخبرك طبيبك بالطريقة المناسبة للقيام بذلك، وعادة ما يكون ذلك بتقليل الجرعة تدريجيًا للمحافظة على أعراض الانسحاب المزعجة في أدنى مستوى لها. انظر أيضًا القسم 2 &quot;أعراض الانسحاب عند التوقف عن تلقي دوروجيسيك&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا توقفت عن استخدام اللاصقات، فلا تضع منها مجددًا قبل استشارة طبيبك. قد تحتاج إلى استخدام لاصقة بتركيز مختلف عند بدء استخدامها مجددًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدامات هذا الدواء، فيمكنك استشارة الطبيب أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن جميع الأدوية، يمكن أن يتسبب هذا الدواء في حدوث آثار جانبية، لكن ليس بالضرورة أن يُصاب بها جميع الأشخاص.</p><p dir="RTL">&nbsp;</p><p>إذا لاحظت أنت أو شريكك أو مقدم الرعاية الخاص بك أيًّا مما يلي بشأن الشخص الذي يضع اللاصقة، فانزع اللاصقة عنه واتصل بالطبيب، أو توجه إلى أقرب مستشفى على الفور. فقد تحتاج إلى علاج طبي عاجل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالنعاس على غير العادة، وان يكون التنفس بطيئًا أو ضحلًا أكثر من المتوقع.</p><p dir="RTL">اتبع النصائح أعلاه واطلب من الشخص الذي كان يضع اللاصقة التحرك وعدم البقاء ساكنًا وحاول فتح حديث معه قدر الإمكان. نادرًا جدًا ما تكون هذه المشكلات المتعلقة بالتنفس مهددة للحياة أو حتى مميتة، وخاصة لدى الأشخاص الذين لم يستخدموا مسكنات ألم أفيونية قوية (مثل الدوروجيسيك أو المورفين). (آثار غير الشائعة، وقد تؤثر على شخص واحد بحد أقصى من بين كل 100 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم المفاجئ للوجه أو الحنجرة، أو حالات التهيج أو الاحمرار، أو التقرحات الشديدة للبشرة. كل هذه قد تكون علامات لردود الفعل التحسسية الشديدة. (لا يمكن تقدير معدل التكرار من البيانات المتوفرة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات (التشنجات) (آثار غير الشائعة، وقد تؤثر على شخص واحد بحد أقصى من بين كل 100 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الوعي أو فقدان الوعي. (آثار غير الشائعة، وقد تؤثر على شخص واحد بحد أقصى من بين كل 100 شخص)</p><p>تم الإبلاغ أيضًا عن أن الآثار الجانبية التالية شائعة جدًا (قد تؤثر على أكثر من شخص من بين كل 10 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان، والقيء، والإمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالنعاس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&nbsp;</p><p>شائعة (قد تؤثر على شخص واحد بحد أقصى من بين كل 10 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالقلق أو الاضطراب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رؤية أشياء غير موجودة بالفعل أو الشعور بها أو سماعها أو شم رائحتها (الهلاوس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتعاش العضلات أو تشنجات العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور غير عادي في الجلد، مثل الشعور بالوخز أو التنَمُّل (التنميل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوران (الدوار)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بتسارع نبضات القلب أو عدم انتظامها (خفقان القلب، أو تسرُّع القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق النفس (الزلة التنفسية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الحلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المعدة أو عسر الهضم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط التعرق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة، أو الطفح الجلدي، أو احمرار الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على التبول أو إفراغ المثانة تمامًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإرهاق التام أو الضعف، أو الشعور بالاعتلال بشكل عام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالبرد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم اليدين، أو الكاحلين، أو القدمين (الوذمة المحيطية)</p><p dir="RTL">&nbsp;</p><p>غير شائعة (يُمكن أن تؤثر على شخص واحد بحد أقصى من بين كل 100 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالاضطراب أو الارتباك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بسعادة مفرطة (النشوة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة الإحساس أو الحساسية، خاصة في الجلد (نقص الحس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الذاكرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرؤية الضبابية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض معدل ضربات القلب (بطء القلب) أو انخفاض ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ازرقاق الجلد بسبب انخفاض مستوى الأكسجين في الدم (الزراق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان انقباضات القناة الهضمية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي وحكة (إكزيما)، أو رد فعل تحسسي، أو اضطرابات جلدية أخرى في مكان وضع اللاصقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض مشابهة لأعراض الإنفلونزا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بانخفاض درجة حرارة الجسم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتعاش العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة الوصول إلى الانتصاب أو المحافظة عليه (العجز الجنسي) أو مشكلات في الجماع</p><p dir="RTL">&nbsp;</p><p>آثار جانبية نادرة (قد تؤثر على شخص واحد بحد أقصى من بين كل 1000 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدقة متقبضة (تقبض الحدقة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توقف التنفس من حين لآخر (انقطاع النفس)</p><p dir="RTL">&nbsp;</p><p>كما تم الإبلاغ عن الآثار الجانبية التالية، ولكن معدل تكرار حدوثها غير معروف على وجه الدقة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الهرمونات الجنسية الذكرية (نقص الأندروجين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهذيان (قد تتضمن الأعراض مزيجًا من الانفعال، والأرق، والتوهان، والاضطراب، والخوف، ورؤية أشياء غير موجودة بالفعل أو سماعها، واضطراب النوم، والكوابيس).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تلاحظ طفحًا جلديًا أو احمرارًا أو حكة طفيفة في الجلد في موضع اللاصقة. عادة ما تكون هذه الأعراض خفيفة وتختفي بعد إزالة اللاصقة. إذا لم يحدث ذلك، أو إذا كانت اللاصقة تهيج بشرتك بشدة، فأخبر طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتسبب الاستخدام المتكرر للَّاصقات في تقليل فعالية الدواء (يعتاد جسمك عليه، أو ربما تصبح أكثر حساسية تجاه الشعور بالألم)، في عدم قدرتك على الاستغناء عنه بعد ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا قمت بالتبديل من مسكن آخر إلى دوروجيسيك أو إذا توقفت فجأة عن استخدام دوروجيسيك، فقد تلاحظ آثار انسحاب؛ مثل المرض، أو الشعور بالغثيان، أو الإسهال، أو القلق، أو الارتجاف. أخبر الطبيب إذا لاحظت حدوث أيٍّ من هذه الآثار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كانت هناك إبلاغات أيضًا عن أطفال حديثي الولادة عانوا من تأثيرات الانسحاب بعد أن استخدمت أمهاتهم دوروجيسيك لفترة طويلة أثناء الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا ابلغ الطبيب المعالج أو الممرضة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>الاحتفاظ باللاصقات</p><p dir="RTL">أبقِ جميع اللاصقات (المستعملة وغير المستعملة) بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">احفظ اللاصقات في عبوتها الأصلية لحمايتها من الضوء.</p><p dir="RTL">احفظ اللاصقات في درجة حرارة أقل من 30 درجة مئوية و في العبوات الأصلية غير المفتوحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">خزّن هذا الدواء في بيئة آمنة بعيدًا عن متناول الآخرين. إذا تلقى شخص الدواء دون قصد، أو بقصد ولم يكن موصوفًا له فقد يسبب له ذلك أضرارًا جسيمة، بل وربما مميتة.</p><p dir="RTL">&nbsp;</p><p>مدة الاحتفاظ بدوروجيسيك</p><p dir="RTL">لا تستخدم دوروجيسيك بعد تاريخ انتهاء الصلاحية المحدد على العبوة الكرتونية أو الكيس. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور. إذا كانت اللاصقات منتهية الصلاحية، فتوجه بها إلى الصيدلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>كيفية التخلص من الملصقات المستعملة أو التي لم تعد تستعملها</p><p dir="RTL">التصاق لاصقة مستعملة أو غير مستعملة بشخص آخر عن طريق الخطأ، وبخاصة إذا كان طفلًا، قد يسبب أضرارًا مميتة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي طي اللاصقات المستعملة من المنتصف جيدًا لكي يلتصق الجزء اللاصق ببعضه. بعد ذلك، يجب التخلص منها بطريقة آمنة عن طريق إعادتها إلى الكيس الأصلي وتخزينها بعيدًا عن مرأى الآخرين ومتناول أيديهم، وبخاصة الأطفال، لحين التخلص منها بطريقة آمنة. استشر الصيدلاني الذي تتعامل معه بشأن كيفية التخلص من الأدوية التي لم تعد تستعملها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">امتنع عن التخلّص من الأدوية بإلقائها في الفضلات السائلة أو المخلفات المنزلية. فهذه الإجراءات من شأنها المساعدة في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>محتويات دوروجيسيك</p><p dir="RTL"><u>دوروجيسيك </u><u>12 ميكروجم/ساعة</u></p><p dir="RTL">المادة الفعالة في دوروجيسيك هي الفينتانيل. تحتوي كل لاصقة على 2.1 مجم &nbsp;من الفينتانيل، وتوصل للجسم جرعة بمقدار 12 ميكروجم/ساعة.</p><p dir="RTL"><u>دوروجيسيك </u><u>25 ميكروجم/ساعة</u></p><p dir="RTL">المادة الفعالة في دوروجيسيك هي الفينتانيل. تحتوي كل لاصقة على 4.2 مجم &nbsp;من الفينتانيل، وتوصل</p><p dir="RTL">للجسم جرعة بمقدار 25 ميكروجم/ساعة.</p><p dir="RTL"><u>دوروجيسيك </u><u>50 ميكروجم/ساعة</u></p><p dir="RTL">المادة الفعالة في دوروجيسيك هي الفينتانيل. تحتوي كل لاصقة على 8.4 مجم &nbsp;من الفينتانيل، وتوصل</p><p dir="RTL">للجسم جرعة بمقدار 50 ميكروجم/ساعة.</p><p dir="RTL"><u>دوروجيسيك </u><u>75 ميكروجم/ساعة</u></p><p dir="RTL">المادة الفعالة في دوروجيسيك هي الفينتانيل. تحتوي كل لاصقة على 12.6 مجم &nbsp;من الفينتانيل، وتوصل</p><p dir="RTL">للجسم جرعة بمقدار 75 ميكروجم/ساعة.</p><p dir="RTL"><u>دوروجيسيك </u><u>100 ميكروجم/ساعة</u></p><p dir="RTL">المادة الفعالة في دوروجيسيك هي الفينتانيل. تحتوي كل لاصقة على 16.8 مجم &nbsp;من الفينتانيل، وتوصل</p><p dir="RTL">للجسم جرعة بمقدار 100 ميكروجم/ساعة.</p><p dir="RTL">&nbsp;</p><p>المكونات الأخرى في اللاصقة:</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">طبقة التغليف:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طبقة رقيقة، البوليستر/كوبوليمر الإيثيلين فينيل أسيتات، بطانة واقية:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طبقة رقيقة، البوليستر السليكوني،</p><p dir="RTL">طبقة الدواء:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بولي أكريليت لاصق</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأحبار (على الغلاف):</p><p dir="RTL">تحتوي لاصقة دوروجيسيك 12 ميكروجم/ساعة أيضًا على حبر طباعة برتقالي.</p><p dir="RTL">تحتوي لاصقة دوروجيسيك 25 ميكروجم/ساعة أيضًا على حبر طباعة أحمر.</p><p dir="RTL">تحتوي لاصقة دوروجيسيك 50 ميكروجم/ساعة أيضًا على حبر طباعة أخضر.</p><p dir="RTL">تحتوي لاصقة دوروجيسيك 75 ميكروجم/ساعة أيضًا على حبر طباعة أزرق.</p><p dir="RTL">تحتوي لاصقة دوروجيسيك 100 ميكروجم/ساعة أيضًا على حبر طباعة رمادي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u>دوروجيسيك </u><u>12 ميكروجم/ساعة</u></p><p dir="RTL">دوروجيسيك هو لاصقة شفافة مستطيلة بزوايا مستديرة. يبلغ طول اللاصقة 5.25 سم<sup>2</sup>، وهي مميزة بإطار وعبارة &quot;دوروجيسيك 12 ميكروجم فنتانيل/ساعة&quot; مطبوعة بحبر طباعة برتقالي.</p><p dir="RTL"><u>دوروجيسيك </u><u>25 ميكروجم/ساعة</u></p><p dir="RTL">دوروجيسيك هو لاصقة شفافة مستطيلة بزوايا مستديرة. يبلغ طول اللاصقة 10.5 سم<sup>2</sup>، وهي</p><p dir="RTL">مميزة بإطار وعبارة &quot;دوروجيسيك 25 ميكروجم فنتانيل/ساعة&quot; مطبوعة بحبر طباعة أحمر.</p><p dir="RTL"><u>دوروجيسيك </u><u>50 ميكروجم/ساعة</u></p><p dir="RTL">دوروجيسيك هو لاصقة شفافة مستطيلة بزوايا مستديرة. يبلغ طول اللاصقة 21.0 سم<sup>2</sup>، وهي</p><p dir="RTL">مميزة بإطار وعبارة &quot;دوروجيسيك 50 ميكروجم فنتانيل/ساعة&quot; مطبوعة بحبر طباعة أخضر.</p><p dir="RTL"><u>دوروجيسيك </u><u>75 ميكروجم/ساعة</u></p><p dir="RTL">دوروجيسيك هو لاصقة شفافة مستطيلة بزوايا مستديرة. يبلغ طول اللاصقة 31.5 سم<sup>2</sup>، وهي</p><p dir="RTL">مميزة بإطار وعبارة &quot;دوروجيسيك 75 ميكروجم فنتانيل/ساعة&quot; مطبوعة بحبر طباعة أرزق.</p><p dir="RTL"><u>دوروجيسيك </u><u>100 ميكروجم/ساعة</u></p><p dir="RTL">دوروجيسيك هو لاصقة شفافة مستطيلة بزوايا مستديرة. يبلغ طول اللاصقة 42.0 سم<sup>2</sup>، وهي</p><p dir="RTL">مميزة بإطار وعبارة &quot;دوروجيسيك 100 ميكروجم فنتانيل/ساعة&quot; مطبوعة بحبر طباعة رمادي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تأتي اللاصقات في أكياس مستقلة مغلفة بالتغليف الحراري (طبقة رقيقة من الأكريلونيتريل أو كوبوليمر أوليفين دوري)، وتأتي في علب كرتونية تحتوي على 3، أو 4، أو 5، أو 8، أو 10، أو 16، أو 20، أو 30 لاصقة.</p><p dir="RTL">لا تتوفر جميع أحجام العبوات في بعض الأسواق.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>حامل ترخيص التسويق:<br />جانسن سيلاج- إن في انتوربيسويج 15-17 بي 2340 بييرس- بلجيكا</p><p>&nbsp;</p><p>&nbsp;</p><p>الجهة المصنعة:</p><p>جانسن فارماسيوتيكا إن ڤي- ترنهوتسويج- 30 - بي-2340 بيرس - بلجيكا</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>للاتصال بنا، يُرجى الانتقال إلى الصفحة </strong><strong>www.janssen.com/contact-us</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ حول الأعراض الجانبية التي قد تحدث يرجى التواصل عبر العناوين التالية</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><ul><li dir="RTL"><strong>المملكة العربية السعودية</strong><strong>:</strong></li></ul><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">المركز الوطني للتيقظ الدوائي :</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفاكس: +966-11-205-7662</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال الموحد: 19999</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: &nbsp;npc.drug@sfda.gov.sa&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><p dir="RTL"><strong>&nbsp;</strong></p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><ul><li dir="RTL"><strong>دول الخليج العربي الأخرى</strong><strong>:</strong></li></ul><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة</p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مجلس وزراء الصحة العرب:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:655px"><tbody><tr><td style="vertical-align:top"><p dir="LTR"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إن هذا دواء</strong></p><p dir="LTR">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدواء مستحضر يؤثر على صحتك واستهلاكه خلافًا للتعليمات يعرضك للخطر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتبع بدقة وصفة الطبيب، وطريقة الاستعمال المنصوص عليها، وتعليمات الصيدلي الذي صرفها لك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطبيب والصيدلي هما الخبيران في الدواء، وفي نفعه وضرره.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تكرر صرف الدواء بدون استشارة الطبيب المختص.</p><p dir="RTL">&nbsp; -&nbsp; لا تترك الأدوية في متناول الاطفال.</p></td></tr></tbody></table><p dir="RTL">مجلس وزراء الصحة العرب</p><p dir="RTL">واتحاد الصيادلة العرب</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تمت الموافقة على هذه النشرة من قبل </strong><strong>الهيئة العامة للغذاء و الدواء</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة في مارس 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 
DUROGESIC and associated names 12 micrograms/hour transdermal patch DUROGESIC and associated names 25 micrograms/hour transdermal patch DUROGESIC and associated names 50 micrograms/hour transdermal patch DUROGESIC and associated names 75 micrograms/hour transdermal patch 
DUROGESIC and associated names 100 micrograms/hour transdermal patch 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 	DUROGESIC® 
Dosage 
(mcg/h) 	Patch Size (cm2) 	Fentanyl Content in Patch (mg) 
DUROGESIC® 	12 	5.25 	2.1 
DUROGESIC® 	25 	10.5 	4.2 
DUROGESIC® 	50 	21.0 	8.4 
DUROGESIC® 	75 	31.5 	12.6 
DUROGESIC® 	100 	42.0 	16.8 

The lowest dose is designated as 12 mcg/h (however, the actual dosage is 12.5 mcg/h) to distinguish it from a 125 mcg/h dosage that could be prescribed by using multiple patches. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Transdermal patch. 
 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adults</p><p>DUROGESIC is indicated for management of severe chronic pain that requires continuous long term opioid administration.</p><p>&nbsp;</p><p>Children</p><p>Long term management of severe chronic pain in children from 2 years of age who are receiving opioid therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p>DUROGESIC doses should be individualised based upon the status of the patient and should be assessed at regular intervals after application. The lowest effective dose should be used. The patches are designed to deliver approximately 12, 25, 50, 75, and 100 mcg/h fentanyl to the systemic circulation, which represent about 0.3, 0.6, 1.2, 1.8, and 2.4 mg per day respectively.</p><p>&nbsp;</p><p>Initial dosage selection</p><p>The appropriate initiating dose of DUROGESIC should be based on the patient&rsquo;s current opioid use. It is recommended that DUROGESIC be used in patients who have demonstrated opioid tolerance. Other factors to be considered are the current general condition and medical status of the patient, including body size, age, and extent of debilitation as well as degree of opioid tolerance.</p><p>&nbsp;</p><p>Adults</p><p>&nbsp;</p><p>Opioid-tolerant patients</p><p>To convert opioid-tolerant patients from oral or parenteral opioids to DUROGESIC refer to Equianalgesic potency conversion below. The dosage may subsequently be titrated upwards or downwards, if required, in increments of either 12 or 25 mcg/h to achieve the lowest appropriate dosage of DUROGESIC depending on response and supplementary analgesic requirements.</p><p>&nbsp;</p><p>Opioid-na&iuml;ve patients</p><p>Generally, the transdermal route is not recommended in opioid-na&iuml;ve patients. Alternative routes of administration (oral, parenteral) should be considered. To prevent overdose it is recommended that opioid-na&iuml;ve patients receive low doses of immediate-release opioids (eg, morphine, hydromorphone, oxycodone, tramadol, and codeine) that are to be titrated until an analgesic dosage equivalent to DUROGESIC with a release rate of 12 mcg/h or 25 mcg/h is attained. Patients can then switch to</p><p>DUROGESIC.</p><p>&nbsp;</p><p>In the circumstance in which commencing with oral opioids is not considered possible and</p><p>DUROGESIC is considered to be the only appropriate treatment option for opioid-na&iuml;ve patients, only the lowest starting dose (ie, 12 mcg/h) should be considered. In such circumstances, the patient must be closely monitored. The potential for serious or life-threatening hypoventilation exists even if the lowest dose of DUROGESIC is used in initiating therapy in opioid-na&iuml;ve patients (see sections 4.4 and 4.9).</p><p>&nbsp;</p><p>Equianalgesic potency conversion</p><p>In patients currently taking opioid analgesics, the starting dose of DUROGESIC should be based on the daily dose of the prior opioid. To calculate the appropriate starting dose of DUROGESIC, follow the steps below.</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Calculate the 24-hour dose (mg/day) of the opioid currently being used.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convert this amount to the equianalgesic 24-hour oral morphine dose using the multiplication factors in Table 1 for the appropriate route of administration.&nbsp;</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To derive the DUROGESIC dosage corresponding to the calculated 24-hour, equianalgesic morphine dosage, use dosage-conversion Table 2 or 3 as follows:</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp; Table 2 is for adult patients who have a need for opioid rotation or who are less clinically stable (conversion ratio of oral morphine to transdermal fentanyl approximately equal to 150:1).&nbsp;</p><p>b.&nbsp;&nbsp;&nbsp; Table 3 is for adult patients who are on a stable, and well-tolerated, opioid regimen (conversion ratio of oral morphine to transdermal fentanyl approximately equal to 100:1).</p><p>&nbsp;</p><p>Table 1: Conversion Table - Multiplication Factors for Converting the Daily Dose of Prior Opioids to the Equianalgesic 24-hour Oral Morphine Dose</p><p>(mg/day Prior Opioid x Factor = Equianalgesic 24-hour Oral Morphine Dose)</p><table border="1" cellspacing="0" cellpadding="0" style="width:604px"><tbody><tr><td style="vertical-align:top"><p><strong>Prior Opioid<sup> </sup></strong></p></td><td style="vertical-align:top"><p><strong>Route of Administration<sup> </sup></strong></p></td><td style="vertical-align:top"><p><strong>Multiplication Factor <sup>&nbsp;</sup></strong></p></td></tr><tr><td rowspan="2"><p><strong>morphine</strong><sup> </sup></p></td><td style="vertical-align:top"><p>oral<sup> </sup></p></td><td style="vertical-align:top"><p>1a</p></td></tr><tr><td style="vertical-align:top"><p>parenteral<sup> </sup></p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td rowspan="2"><p><strong>buprenorphine<sup> </sup></strong></p></td><td style="vertical-align:top"><p>sublingual</p></td><td style="vertical-align:top"><p>75<sup> </sup></p></td></tr><tr><td style="vertical-align:top"><p>parenteral<sup> </sup></p></td><td style="vertical-align:top"><p>100<sup> </sup></p></td></tr><tr><td rowspan="2"><p><strong>codeine<sup> </sup></strong></p></td><td style="vertical-align:top"><p>oral<sup> </sup></p></td><td style="vertical-align:top"><p>0.15</p></td></tr><tr><td style="vertical-align:top"><p>parenteral<sup> </sup></p></td><td style="vertical-align:top"><p>0.23<sup>b</sup></p></td></tr><tr><td rowspan="2"><p><strong>diamorphine<sup> </sup></strong></p></td><td style="vertical-align:top"><p>oral<sup> </sup></p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p>parenteral<sup> </sup></p></td><td style="vertical-align:top"><p>6<sup>b</sup></p></td></tr><tr><td rowspan="2"><p><strong>fentanyl<sup> </sup></strong></p></td><td style="vertical-align:top"><p>oral<sup> </sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>parenteral<sup> </sup></p></td><td style="vertical-align:top"><p>300</p></td></tr><tr><td style="vertical-align:top"><p><strong>hydromorphone<sup> </sup></strong></p></td><td style="vertical-align:top"><p>oral<sup> </sup></p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>parenteral<sup> </sup></p></td><td style="vertical-align:top"><p>20<sup>b</sup></p></td></tr><tr><td rowspan="2"><p><strong>ketobemidone<sup> </sup></strong></p></td><td style="vertical-align:top"><p>oral<sup> </sup></p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>parenteral<sup> </sup></p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td rowspan="2"><p><strong>levorphanol<sup> </sup></strong></p></td><td style="vertical-align:top"><p>oral<sup> </sup></p></td><td style="vertical-align:top"><p>7.5</p></td></tr><tr><td style="vertical-align:top"><p>parenteral<sup> </sup></p></td><td style="vertical-align:top"><p>15<sup>b</sup></p></td></tr><tr><td rowspan="2"><p><strong>methadone<sup> </sup></strong></p></td><td style="vertical-align:top"><p>oral<sup> </sup></p></td><td style="vertical-align:top"><p>1.5</p></td></tr><tr><td style="vertical-align:top"><p>parenteral<sup> </sup></p></td><td style="vertical-align:top"><p>3<sup>b</sup></p></td></tr><tr><td rowspan="2"><p><strong>oxycodone<sup> </sup></strong></p></td><td style="vertical-align:top"><p>oral<sup> </sup></p></td><td style="vertical-align:top"><p>1.5</p></td></tr><tr><td style="vertical-align:top"><p>parenteral<sup> </sup></p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td rowspan="2"><p><strong>oxymorphone<sup> </sup></strong></p></td><td style="vertical-align:top"><p>rectal<sup> </sup></p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>parenteral<sup> </sup></p></td><td style="vertical-align:top"><p>30<sup>b</sup></p></td></tr><tr><td rowspan="2"><p><strong>pethidine<sup> </sup></strong></p></td><td style="vertical-align:top"><p>oral<sup> </sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>parenteral<sup> </sup></p></td><td style="vertical-align:top"><p>0.4<sup>b</sup></p></td></tr><tr><td rowspan="2"><p><strong>tapentadol<sup> </sup></strong></p></td><td style="vertical-align:top"><p>oral<sup> </sup></p></td><td style="vertical-align:top"><p>0.4</p></td></tr><tr><td style="vertical-align:top"><p>parenteral<sup> </sup></p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="2"><p><strong>tramadol<sup> </sup></strong></p></td><td style="vertical-align:top"><p>oral<sup> </sup></p></td><td style="vertical-align:top"><p>0.25</p></td></tr><tr><td style="vertical-align:top"><p>parenteral<sup> </sup></p></td><td style="vertical-align:top"><p>0.3</p></td></tr></tbody></table><p>&nbsp;</p><p><sup>a</sup> The oral/IM potency for morphine is based on clinical experience in patients with chronic pain. <sup>b</sup> Based on single-dose studies in which an IM dose of each active substance listed was compared with morphine to establish the relative potency. Oral doses are those recommended when changing from a parenteral to an oral route.</p><p>&nbsp;</p><p>Reference: Adapted from 1) Foley KM. The treatment of cancer pain. NEJM 1985; 313 (2): 84-95 and</p><p>2) McPherson ML. Introduction to opioid conversion calculations. In: Demystifying Opioid Conversion Calculations: A Guide for Effective Dosing. Bethesda, MD: American Society of HealthSystem Pharmacists; 2010:1-15.</p><p>&nbsp;</p><p>Table 2: Recommended starting dosage of DUROGESIC based upon daily oral morphine dose (for</p><p>patients who have a need for opioid rotation or for clinically less stable patients: conversion ratio of oral morphine to transdermal fentanyl is approximately equal to 150:1) <sup>1</sup></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:619px"><tbody><tr><td style="vertical-align:bottom"><p><strong>Oral 24-hour morphine (mg/day) </strong></p></td><td style="vertical-align:top"><p><strong>DUROGESIC </strong></p><p><strong>Dosage </strong></p><p><strong>(mcg/h) </strong></p></td></tr><tr><td style="vertical-align:top"><p>&lt;90</p><p>90-134</p></td><td style="vertical-align:top"><p>12</p><p>25</p></td></tr><tr><td style="vertical-align:top"><p>135-224</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p>225-314</p></td><td style="vertical-align:top"><p>75</p></td></tr><tr><td style="vertical-align:top"><p>315-404</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>405-494</p></td><td style="vertical-align:top"><p>125</p></td></tr><tr><td style="vertical-align:top"><p>495-584</p></td><td style="vertical-align:top"><p>150</p></td></tr><tr><td style="vertical-align:top"><p>585-674</p></td><td style="vertical-align:top"><p>175</p></td></tr><tr><td style="vertical-align:top"><p>675-764</p></td><td style="vertical-align:top"><p>200</p></td></tr><tr><td style="vertical-align:top"><p>765-854</p></td><td style="vertical-align:top"><p>225</p></td></tr><tr><td style="vertical-align:top"><p>855-944</p></td><td style="vertical-align:top"><p>250</p></td></tr><tr><td style="vertical-align:top"><p>945-1034</p></td><td style="vertical-align:top"><p>275</p></td></tr><tr><td style="vertical-align:top"><p>1035-1124</p></td><td style="vertical-align:top"><p>300</p></td></tr></tbody></table><p>&nbsp;</p><p><sup>1</sup> In clinical studies these ranges of daily oral morphine doses were used as a basis for conversion to DUROGESIC.&nbsp;</p><p>Table 3: Recommended starting dosage of DUROGESIC based upon d</p><p><img alt="" width="887" height="424" src="data:image/png;base64,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" /></p><p>Initial evaluation of the maximum analgesic effect of DUROGESIC cannot be made before the patch is worn for 24 hours. This delay is due to the gradual increase in serum fentanyl concentration in the 24 hours following initial patch application.</p><p>&nbsp;</p><p>Previous analgesic therapy should therefore be gradually phased out after the initial dose application until analgesic efficacy with DUROGESIC is attained.</p><p>&nbsp;</p><p><em>Dose titration and maintenance therapy</em><em> </em></p><p>The DUROGESIC patch should be replaced every 72 hours.</p><p>&nbsp;</p><p>The dose should be titrated individually on the basis of average daily use of supplemental analgesics, until a balance between analgesic efficacy and tolerability is attained. Dosage titration should normally be performed in 12 mcg/h or 25 mcg/h increments, although the supplementary analgesic requirements (oral morphine 45/90 mg/day <sub>&asymp;</sub> DUROGESIC 12/25 mcg/h) and pain status of the patient should be taken into account. After an increase in dose, it may take up to 6 days for the patient to reach equilibrium on the new dose level. Therefore, after a dose increase, patients should wear the higher dose patch through two 72-hour applications before any further increase in dose level is made.</p><p>&nbsp;</p><p>More than one DUROGESIC patch may be used for doses greater than 100 mcg/h. Patients may require periodic supplemental doses of a short acting analgesic for &ldquo;breakthrough&rdquo; pain. Some patients may require additional or alternative methods of opioid administration when the DUROGESIC dose exceeds 300 mcg/h.</p><p>&nbsp;</p><p>If analgesia is insufficient during the first application only, the DUROGESIC patch may be replaced after 48 hours with a patch of the same dose, or the dose may be increased after 72 hours.</p><p>&nbsp;</p><p>If the patch needs to be replaced (eg, the patch falls off) before 72 hours, a patch of the same strength should be applied to a different skin site. This may result in increased serum concentrations (see section 5.2) and the patient should be monitored closely.</p><p>&nbsp;</p><p><em>Discontinuation of DUROGESIC</em><em> </em></p><p>If discontinuation of DUROGESIC is necessary, replacement with other opioids should be gradual, starting at a low dose and increasing slowly. This is because fentanyl concentrations fall gradually after DUROGESIC is removed. It may take 20 hours or more for the fentanyl serum concentrations to decrease 50%. In general, the discontinuation of opioid analgesia should be gradual in order to prevent withdrawal symptoms (see section 4.8).</p><p>&nbsp;</p><p>Opioid withdrawal symptoms are possible in some patients after conversion or dose adjustment.</p><p>&nbsp;</p><p>Tables 1, 2, and 3 should only be used to convert from other opioids to DUROGESIC and not from DUROGESIC to other therapies to avoid overestimating the new analgesic dose and potentially causing overdose.</p><p><em>&nbsp;</em></p><p><em><u>Special populations</u> </em></p><p>&nbsp;</p><p><em>Elderly patients </em></p><p>Elderly patients should be observed carefully and the dose should be individualized based upon the status of the patient (see sections 4.4 and 5.2).&nbsp;</p><p>&nbsp;</p><p>In opioid-na&iuml;ve elderly patients, treatment should only be considered if the benefits outweigh the risks. In these cases, only DUROGESIC 12 mcg/h dosage should be considered for initial treatment.&nbsp;</p><p>&nbsp;</p><p><em>Renal and hepatic impairment </em></p><p>Patients with renal or hepatic impairment should be observed carefully and the dose should be individualized based upon the status of the patient (see sections 4.4 and 5.2).&nbsp;</p><p>&nbsp;</p><p>In opioid-na&iuml;ve patients with renal or hepatic impairment, treatment should only be considered if the benefits outweigh the risks. In these cases, only DUROGESIC 12 mcg/h dosage should be considered for initial treatment.&nbsp;</p><p>&nbsp;</p><p>Pediatric population</p><p>&nbsp;</p><p><em>Children aged 16 years and above</em> Follow adult dosage.</p><p>&nbsp;</p><p><em>Children 2 to 16 years old</em></p><p>DUROGESIC should be administered to only those opioid-tolerant pediatric patients (ages 2 to 16 years) who are already receiving at least 30 mg oral morphine equivalents per day. To convert pediatric patients from oral or parenteral opioids to DUROGESIC, refer to Equianalgesic potency conversion (Table 1) and Recommended DUROGESIC dosage based upon daily oral morphine dose (Table 4).</p><p>&nbsp;</p><p>Table 4: Recommended DUROGESIC dosage for pediatric patients<sup>1</sup> based upon daily oral morphine dose<sup>2</sup></p><p><img alt="" width="795" height="233" src="data:image/png;base64,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" /></p><p>In two pediatric studies, the required fentanyl transdermal patch dose was calculated conservatively:</p><p>30 mg to 44 mg oral morphine per day or its equivalent opioid dose was replaced by one DUROGESIC 12 mcg/h patch. It should be noted that this conversion schedule for children only applies to the switch from oral morphine (or its equivalent) to DUROGESIC patches. The conversion schedule should not be used to convert from DUROGESIC into other opioids, as overdosing could then occur.</p><p>&nbsp;</p><p>The analgesic effect of the first dose of DUROGESIC patches will not be optimal within the first 24 hours. Therefore, during the first 12 hours after switching to DUROGESIC, the patient should be given the previous regular dose of analgesics. In the next 12 hours, these analgesics should be provided based on clinical need.</p><p>&nbsp;</p><p>Monitoring of the patient for adverse events, which may include hypoventilation, is recommended for at least 48 hours after initiation of DUROGESIC therapy or up-titration of the dose (see section 4.4).</p><p>&nbsp;</p><p>DUROGESIC should not be used in children aged less than 2 years because the safety and efficacy have not been established.<em> </em></p><p>&nbsp;</p><p><em>Dose titration and maintenance in children </em></p><p>The DUROGESIC patch should be replaced every 72 hours. The dose should be titrated individually until a balance between analgesic efficacy and tolerability is attained. Dosage must not be increased in intervals of less than 72 hours. If the analgesic effect of DUROGESIC is insufficient, supplementary morphine or another short-duration opioid should be administered. Depending on the additional analgesic needs and the pain status of the child, it may be decided to increase the dose. Dose adjustments should be done in 12 mcg/h steps.</p><p>&nbsp;</p><p>Method of administration<strong> </strong></p><p>DUROGESIC is for transdermal use.</p><p>DUROGESIC should be applied to non-irritated and non-irradiated skin on a flat surface of the torso or upper arms.</p><p>&nbsp;</p><p>In young children, the upper back is the preferred location to minimize the potential of the child removing the patch.&nbsp;</p><p>&nbsp;</p><p>Hair at the application site (a non-hairy area is preferable) should be clipped (not shaved) prior to application. If the site of DUROGESIC application requires cleansing prior to application of the patch, this should be done with clear water. Soaps, oils, lotions, or any other agent that might irritate the skin or alter its characteristics should not be used. The skin should be completely dry before the patch is applied. Patches should be inspected prior to use. Patches that are cut, divided, or damaged in any way should not be used.</p><p>&nbsp;</p><p>DUROGESIC should be applied immediately upon removal from the sealed package. To remove the patch from the protective sachet, locate the pre-cut notch (indicated by an arrow on the patch label) along the edge of the seal. Fold the sachet at the notch, then carefully tear the sachet material. Further open the sachet along both sides, folding the sachet open like a book. The release liner for the patch is slit. Fold the patch in the middle and remove each half of the liner separately. Avoid touching the adhesive side of the patch. Apply the patch to the skin by applying light pressure with the palm of the hand for about 30 seconds. Make certain that the edges of the patch are adhering properly. Then wash hands with clean water.</p><p>&nbsp;</p><p>DUROGESIC may be worn continuously for 72 hours. A new patch should be applied to a different skin site after removal of the previous transdermal patch. Several days should elapse before a new patch is applied to the same area of the skin.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
 
Acute or postoperative pain because there is no opportunity for dose titration during short-term use and because serious or life-threatening hypoventilation could result. 
 
Severe respiratory depression. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients who have experienced serious adverse events should be monitored for at least 24 hours after removal of DUROGESIC, or more, as clinical symptoms dictate, because serum fentanyl concentrations decline gradually and are reduced by about 50% 20 to 27 hours later.</p><p>&nbsp;</p><p>Patients and their carers must be instructed that DUROGESIC contains an active substance in an amount that can be fatal, especially to a child. Therefore, they must keep all patches out of the sight and reach of children, both before and after use.</p><p>&nbsp;</p><p>Opioid-na&iuml;ve and not opioid-tolerant states</p><p>Use of DUROGESIC in the opioid-na&iuml;ve patient has been associated with very rare cases of significant respiratory depression and/or fatality when used as initial opioid therapy, especially in patients with non-cancer pain. The potential for serious or life-threatening hypoventilation exists even if the lowest dose of DUROGESIC is used in initiating therapy in opioid-na&iuml;ve patients, especially in elderly or patients with hepatic or renal impairment. The tendency of tolerance development varies widely among individuals. It is recommended that DUROGESIC is used in patients who have demonstrated opioid tolerance (see section 4.2).</p><p>&nbsp;</p><p>Respiratory depression</p><p>Some patients may experience significant respiratory depression with DUROGESIC; patients must be observed for these effects. Respiratory depression may persist beyond the removal of the</p><p>DUROGESIC patch. The incidence of respiratory depression increases as the DUROGESIC dose is increased (see section 4.9). Central nervous system depressants may increase the respiratory depression (see section 4.5).</p><p>&nbsp;</p><p>Chronic pulmonary disease</p><p>DUROGESIC may have more severe adverse effects in patients with chronic obstructive or other pulmonary disease. In such patients, opioids may decrease respiratory drive and increase airway resistance.</p><p>&nbsp;</p><p>Drug dependence and potential for abuse</p><p>Tolerance, physical dependence, and psychological dependence may develop upon repeated administration of opioids.&nbsp;</p><p>&nbsp;</p><p>Fentanyl can be abused in a manner similar to other opioid agonists. Abuse or intentional misuse of DUROGESIC may result in overdose and/or death. Patients with a prior history of drug dependence/alcohol abuse are more at risk to develop dependence and abuse in opioid treatment. Patients at increased risk of opioid abuse may still be appropriately treated with modified-release opioid formulations; however, these patients will require monitoring for signs of misuse, abuse, or addiction.&nbsp;</p><p>&nbsp;</p><p>Central Nervous System conditions including increased intracranial pressure</p><p>DUROGESIC should be used with caution in patients who may be particularly susceptible to the intracranial effects of CO<sub>2</sub> retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. DUROGESIC should be used with caution in patients with brain tumors.</p><p>&nbsp;</p><p>Cardiac disease</p><p>Fentanyl may produce bradycardia and should therefore be administered with caution to patients with bradyarrhythmias.</p><p>&nbsp;</p><p>Hypotension</p><p>Opioids may cause hypotension, especially in patients with acute hypovolemia. Underlying, symptomatic hypotension and/or hypovolemia should be corrected before treatment with fentanyl transdermal patches is initiated.</p><p><em>&nbsp;</em></p><p>Hepatic impairment</p><p>Because fentanyl is metabolized to inactive metabolites in the liver, hepatic impairment might delay its elimination. If patients with hepatic impairment receive DUROGESIC, they should be observed carefully for signs of fentanyl toxicity and the dose of DUROGESIC reduced if necessary (see section 5.2).</p><p>&nbsp;</p><p>Renal impairment</p><p>Even though impairment of renal function is not expected to affect fentanyl elimination to a clinically relevant extent, caution is advised because fentanyl pharmacokinetics has not been evaluated in this patient population (see section 5.2).&nbsp; If patients with renal impairment receive DUROGESIC, they should be observed carefully for signs of fentanyl toxicity and the dose reduced if necessary. Additional restrictions apply to opioid-na&iuml;ve patients with renal impairment (see section 4.2).</p><p>&nbsp;</p><p>Fever/external heat application</p><p>Fentanyl concentrations may increase if the skin temperature increases (see section 5.2). Therefore, patients with fever should be monitored for opioid undesirable effects and the DUROGESIC dose should be adjusted if necessary. There is a potential for temperature-dependent increases in fentanyl released from the system resulting in possible overdose and death.</p><p>&nbsp;</p><p>All patients should be advised to avoid exposing the DUROGESIC application site to direct external heat sources such as heating pads, electric blankets, heated water beds, heat or tanning lamps, sunbathing, hot water bottles, prolonged hot baths, saunas and hot whirlpool spa baths.</p><p>&nbsp;</p><p>Serotonin syndrome</p><p>Caution is advised when DUROGESIC is co-administered with medicinal products that affect the serotonergic neurotransmitter systems.&nbsp;</p><p>&nbsp;</p><p>The development of a potentially life-threatening serotonin syndrome may occur with the concomitant use of serotonergic active substances such as Selective Serotonin Re-uptake Inhibitors (SSRIs) and Serotonin Norepinephrine Re-uptake Inhibitors (SNRIs), and with active substances which impair metabolism of serotonin (including Monoamine Oxidase Inhibitors [MAOIs]). This may occur within the recommended dose.</p><p>&nbsp;</p><p>Serotonin syndrome may include mental-status changes (eg, agitation, hallucinations, coma), autonomic instability (eg, tachycardia, labile blood pressure, hyperthermia), neuromuscular abnormalities (eg, hyperreflexia, incoordination, rigidity), and/or gastrointestinal symptoms (eg, nausea, vomiting, diarrhea).</p><p>&nbsp;</p><p>If serotonin syndrome is suspected, treatment with DUROGESIC should be discontinued.</p><p>&nbsp;</p><p><em><u>Interactions with other medicinal products</u> </em></p><p>CYP3A4 inhibitors</p><p>The concomitant use of DUROGESIC with cytochrome P450 3A4 (CYP3A4) inhibitors may result in an increase in fentanyl plasma concentrations, which could increase or prolong both the therapeutic and adverse effects, and may cause serious respiratory depression. Therefore, the concomitant use of DUROGESIC and CYP3A4 inhibitors is not recommended unless the benefits outweigh the increased risk of adverse effects. Generally, a patient should wait for 2 days after stopping treatment with a CYP3A4 inhibitor before applying the first DUROGESIC patch. However, the duration of inhibition varies and for some CYP3A4 inhibitors with a long elimination half-life, such as amiodarone, or for time-dependent inhibitors such as erythromycin, idealistic, nicardipine and ritonavir, this period may need to be longer. Therefore, the product information of the CYP3A4 inhibitor must be consulted for the active substance&rsquo;s half-life and duration of the inhibitory effect before applying the first DUROGESIC patch. A patient who is treated with DUROGESIC should wait at least 1 week after removal of the last patch before initiating treatment with a CYP3A4 inhibitor. If concomitant use of DUROGESIC with a CYP3A4 inhibitor cannot be avoided, close monitoring for signs or symptoms of increased or prolonged therapeutic effects and adverse effects of fentanyl (in particular respiratory depression) is warranted, and the DUROGESIC dosage must be reduced or interrupted as deemed necessary (see section 4.5).</p><p>&nbsp;</p><p>Accidental exposure by patch transfer</p><p>Accidental transfer of a fentanyl patch to the skin of a non-patch wearer (particularly a child), while sharing a bed or being in close physical contact with a patch wearer, may result in an opioid overdose for the non-patch wearer. Patients should be advised that if accidental patch transfer occurs, the transferred patch must be removed immediately from the skin of the non-patch wearer (see section 4.9).</p><p>&nbsp;</p><p>Use in elderly patients</p><p>Data from intravenous studies with fentanyl suggest that elderly patients may have reduced clearance, a prolonged half-life, and they may be more sensitive to the active substance than younger patients. If elderly patients receive DUROGESIC, they should be observed carefully for signs of fentanyl toxicity and the dose reduced if necessary (see section 5.2).</p><p>&nbsp;</p><p>Gastrointestinal tract&nbsp;</p><p>Opioids increase the tone and decrease the propulsive contractions of the smooth muscle of the gastrointestinal tract. The resultant prolongation in gastrointestinal transit time may be responsible for the constipating effect of fentanyl. Patients should be advised on measures to prevent constipation and prophylactic laxative use should be considered. Extra caution should be used in patients with chronic constipation. If paralytic ileus is present or suspected, treatment with DUROGESIC should be stopped.</p><p>&nbsp;</p><p>Patients with myasthenia gravis</p><p>Non-epileptic (myo)clinic reactions can occur. Caution should be exercised when treating patients with myasthenia gravis.<strong> </strong></p><p>&nbsp;</p><p>Concomitant use of mixed opioid agonists/antagonists</p><p>The concomitant use of buprenorphine, nalbuphine or pentazocine is not recommended (see also section 4.5).<strong> </strong></p><p>&nbsp;</p><p>Pediatric population</p><p>DUROGESIC<sup> </sup>should not be administered to opioid-na&iuml;ve pediatric patients<strong> </strong>(see section 4.2). The potential for serious or life-threatening hypoventilation exists regardless of the dose of DUROGESIC<sup> </sup>transdermal system administered.&nbsp;</p><p><strong>&nbsp;</strong></p><p>DUROGESIC has not been studied in children under 2 years of age. DUROGESIC should be administered only to opioid-tolerant children age 2 years or older (see section 4.2).</p><p>&nbsp;</p><p>To guard against accidental ingestion by children, use caution when choosing the application site for DUROGESIC (see sections 4.2 and 6.6) and monitor adhesion of the patch closely.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacodynamic-related interactions</p><p>&nbsp;</p><p>Centrally-acting medicinal products and alcohol</p><p>The concomitant use of other central nervous system depressants, (including opioids, sedatives, hypnotics, general anesthetics, phenothiazines, tranquilizers, sedating antihistamines, and alcoholic beverages) and skeletal muscle relaxants, may produce additive depressant effects; hypoventilation, hypotension, profound sedation, coma or death may occur. Therefore, the use of any of these medicinal products concomitantly with DUROGESIC requires special patient care and observation.</p><p><em>&nbsp;</em></p><p>Monoamine Oxidase Inhibitors (MAOI)</p><p>DUROGESIC is not recommended for use in patients who require the concomitant administration of an MAOI. Severe and unpredictable interactions with MAOIs, involving the potentiation of opiate effects or the potentiation of serotoninergic effects, have been reported. Therefore, DUROGESIC should not be used within 14 days after discontinuation of treatment with MAOIs.</p><p><em>&nbsp;</em></p><p>Serotonergic medicinal products</p><p>Co-administration of fentanyl with a serotonergic medicinal products, such as a Selective Serotonin</p><p>Re-uptake Inhibitor (SSRI) or a Serotonin Norepinephrine Re-uptake Inhibitor (SNRI) or a</p><p>Monoamine Oxidase Inhibitor (MAOI), may increase the risk of serotonin syndrome, a potentially life threatening condition.</p><p><em>&nbsp;</em></p><p>Concomitant use of mixed opioid agonists/antagonists</p><p>The concomitant use of buprenorphine, nalbuphine or pentazocine is not recommended. They have high affinity to opioid receptors with relatively low intrinsic activity and therefore partially antagonize the analgesic effect of fentanyl and may induce withdrawal symptoms in opioid dependent patients (see also Section 4.4).</p><p>&nbsp;</p><p>Pharmacokinetic-related interactions</p><p>&nbsp;</p><p>CYP3A4 Inhibitors</p><p>Fentanyl, a high clearance active substance, is rapidly and extensively metabolized mainly by CYP3A4.</p><p>&nbsp;</p><p>The concomitant use of DUROGESIC with cytochrome P450 3A4 (CYP3A4) inhibitors may result in an increase in fentanyl plasma concentrations, which could increase or prolong both the therapeutic and adverse effects, and may cause serious respiratory depression. The extent of interaction with strong CYP3A4 inhibitors is expected to be greater than with weak or moderate CYP3A4 inhibitors. Cases of serious respiratory depression after coadministration of CYP3A4 inhibitors with transdermal fentanyl have been reported, including a fatal case after coadministration with a moderate CYP3A4 inhibitor. The concomitant use of CYP3A4 inhibitors and DUROGESIC is not recommended, unless the patient is closely monitored (see section 4.4). Examples of active substances that may increase fentanyl concentrations include: amiodarone, cimetidine, clarithromycin, diltiazem, erythromycin, fluconazole, itraconazole, ketoconazole, nefazodone, ritonavir, verapamil and voriconazole (this list is not exhaustive). After coadministration of weak, moderate or strong CYP3A4 inhibitors with short term intravenous fentanyl administration, decreases in fentanyl clearance were generally <sub>&le;</sub>25%, however with ritonavir (a strong CYP3A4 inhibitor), fentanyl clearance decreased on average 67%. The extent of the interactions of CYP3A4 inhibitors with long-term transdermal fentanyl administration is not known, but may be greater than with short-term intravenous administration.</p><p>&nbsp;</p><p>CYP3A4 Inducers</p><p>The concomitant use of transdermal fentanyl with CYP3A4 inducers may result in a decrease in fentanyl plasma concentrations and a decreased therapeutic effect. Caution is advised upon concomitant use of CYP3A4 inducers and DUROGESIC. The dose of DUROGESIC may need to be increased or a switch to another analgesic active substance may be needed. A fentanyl dose decrease and careful monitoring is warranted in anticipation of stopping concomitant treatment with a CYP3A4 inducer. The effects of the inducer decline gradually and may result in increased fentanyl plasma concentrations, which could increase or prolong both the therapeutic and adverse effects, and may cause serious respiratory depression. Careful monitoring should be continued until stable drug effects are achieved. Examples of active substance that may decrease fentanyl plasma concentrations include:</p><p>carbamazepine, phenobarbital, phenytoin and rifampicin (this list is not exhaustive).</p><p><em>&nbsp;</em></p><p>Pediatric population</p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>There are no adequate data from the use of DUROGESIC in pregnant women. Studies in animals have shown some reproductive toxicity (see section 5.3). The potential risk for humans is unknown, although fentanyl as an IV anesthetic has been found to cross the placenta in human pregnancies. Neonatal withdrawal syndrome has been reported in newborn infants with chronic maternal use of DUROGESIC during pregnancy. DUROGESIC should not be used during pregnancy unless clearly necessary.</p><p>&nbsp;</p><p>Use of DUROGESIC during childbirth is not recommended because it should not be used in the management of acute or postoperative pain (see section 4.3). Moreover, because fentanyl passes through the placenta, the use of DUROGESIC during childbirth might result in respiratory depression in the newborn infant.</p><p>&nbsp;</p><p>Breastfeeding</p><p>Fentanyl is excreted into human milk and may cause sedation/respiratory depression in a breastfed infant. Breastfeeding should therefore be discontinued during treatment with DUROGESIC and for at least 72 hours after removal of the patch.</p><p>&nbsp;</p><p>Fertility</p><p>There are no clinical data on the effects of fentanyl on fertility. Some studies in rats have revealed reduced fertility and enhanced embryo mortality at maternally toxic doses (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>DUROGESIC may impair mental and/or physical ability required for the performance of potentially hazardous tasks such as driving or operating machinery.<em> </em></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety of DUROGESIC was evaluated in 1565 adult and 289 pediatric subjects who participated in 11 clinical studies (1 double-blind, placebo-controlled; 7 open-label, active-controlled; 3 open label, uncontrolled) used for the management of chronic malignant or non-malignant pain. These subjects received at least one dose of DUROGESIC and provided safety data. Based on pooled safety data from these clinical studies, the most commonly reported (ie &ge;10% incidence) adverse reactions were: nausea (35.7%), vomiting (23.2%), constipation (23.1%), somnolence (15.0%), dizziness (13.1%), and headache (11.8%).</p><p>&nbsp;</p><p>The adverse reactions reported with the use of DUROGESIC from these clinical studies, including the above-mentioned adverse reactions, and from post-marketing experiences are listed below in Table 5.</p><p>&nbsp;</p><p>The displayed frequency categories use the following convention: very common (&ge;1/10); common</p><p>(&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available clinical data). The adverse reactions are presented by System Organ Class and in order of decreasing seriousness within each frequency category.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:619px"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 5: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions in adult and paediatric patients </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>System/organ class</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Frequency category </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic shock, Anaphylactic reaction, Anaphylactoid reaction</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Insomnia,</p><p>Depression,</p><p>Anxiety,</p><p>Confusional state,</p><p>Hallucination</p></td><td style="vertical-align:top"><p>Agitation,</p><p>Disorientation,</p><p>Euphoric mood&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders </strong></p></td><td style="vertical-align:top"><p>Somnolence,</p><p>Dizziness,</p><p>Headache&nbsp;</p></td><td style="vertical-align:top"><p>Tremor,</p><p>Paraesthesia&nbsp;</p></td><td style="vertical-align:top"><p>Hypoaesthesia,</p><p>Convulsion (including clonic convulsions and grand mal convulsion),</p><p>Amnesia,</p><p>Depressed level of consciousness, Loss of consciousness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vision blurred</p></td><td style="vertical-align:top"><p>Miosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Palpitations, Tachycardia</p></td><td style="vertical-align:top"><p>Bradycardia, Cyanosis&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>Respiratory depression,</p><p>Respiratory distress&nbsp;</p></td><td style="vertical-align:top"><p>Apnoea, Hypoven</p><p>tilation</p></td><td style="vertical-align:top"><p>Bradypnoea</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders </strong></p></td><td style="vertical-align:top"><p>Nausea,</p><p>Vomiting,</p><p>Constipation</p></td><td style="vertical-align:top"><p>Diarrhoea, Dry mouth,</p><p>Abdominal pain, Abdominal pain upper, Dyspepsia</p></td><td style="vertical-align:top"><p>Ileus</p></td><td style="vertical-align:top"><p>Subileus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperhidrosis, Pruritus, Rash,</p><p>Erythema&nbsp;</p></td><td style="vertical-align:top"><p>Eczema, Dermatitis allergic, Skin disorder, Dermatitis,</p><p>Dermatitis contact&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscle spasms</p></td><td style="vertical-align:top"><p>Muscle twitching</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Urinary retention</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Erectile</p><p>dysfunction, Sexual dysfunction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fatigue, Oedema peripheral,</p><p>Asthenia, Malaise,</p><p>Feeling cold&nbsp;</p></td><td style="vertical-align:top"><p>Application site reaction, Influenzalike illness, Feeling of body temperature change,</p><p>Application site hypersensitivity, Drug withdrawal syndrome, Pyrexia<sup>*</sup></p></td><td style="vertical-align:top"><p>Applicati on site dermatitis</p><p>&nbsp;</p><p>Application site eczema&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><sup>* </sup>the assigned frequency (uncommon) is based on analyses of incidence including only adult and paediatric clinical study subjects with non-cancer pain.</p><p>&nbsp;</p><p>Paediatric population</p><p>The safety of DUROGESIC was evaluated in 289 paediatric subjects (&lt;18 years) who participated in 3 clinical studies for the management of chronic or continuous pain of malignant or non-malignant origin. These subjects received at least one dose of DUROGESIC and provided safety data (see section 5.1).</p><p>&nbsp;</p><p>The safety profile in children and adolescents treated with DUROGESIC was similar to that observed in adults. No risk was identified in the paediatric population beyond that expected with the use of opioids for the relief of pain associated with serious illness and there does not appear to be any paediatric-specific risk associated with DUROGESIC use in children as young as 2 years old when used as directed. <strong>&nbsp;</strong></p><p>&nbsp;</p><p>Based on pooled safety data from these 3 clinical studies in paediatric subjects, the most commonly reported (i.e. &ge;10% incidence) adverse reactions were vomiting (33.9%), nausea (23.5%), headache (16.3%), constipation (13.5%), diarrhoea (12.8%), and pruritus (12.8%).</p><p>&nbsp;</p><p>Tolerance, physical dependence, and psychological dependence can develop on repeated use of DUROGESIC (see section 4.4).</p><p>&nbsp;</p><p>Opioid withdrawal symptoms (such as nausea, vomiting, diarrhoea, anxiety, and shivering) are possible in some patients after conversion from their previous opioid analgesic to DUROGESIC or if therapy is stopped suddenly (see section 4.2).</p><p>&nbsp;</p><p>There have been very rare reports of newborn infants experiencing neonatal withdrawal syndrome when mothers chronically used DUROGESIC during pregnancy (see section 4.6).</p><p>&nbsp;</p><p>Cases of serotonin syndrome have been reported when fentanyl was administered concomitantly with highly serotonergic drugs (see sections 4.4. and 4.5).</p><p>&nbsp;</p><p>Reporting of suspected adverse reactions</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms and signs</p><p>The manifestations of fentanyl overdose are an extension of its pharmacologic actions, the most serious effect being respiratory depression.</p><p>&nbsp;</p><p>Treatment</p><p>For management of respiratory depression, immediate countermeasures include removing the DUROGESIC patch and physically or verbally stimulating the patient. These actions can be followed by administration of a specific opioid antagonist such as naloxone. Respiratory depression following an overdose may outlast the duration of action of the opioid antagonist. The interval between IV antagonist doses should be carefully chosen because of the possibility of re-narcotization after the patch is removed; repeated administration or a continuous infusion of naloxone may be necessary. Reversal of the narcotic effect may result in acute onset of pain and release of catecholamines.</p><p>&nbsp;</p><p>If the clinical situation warrants, a patent airway should be established and maintained, possibly with an oropharyngeal airway or endotracheal tube, and oxygen should be administered and respiration assisted or controlled, as appropriate. Adequate body temperature and fluid intake should be maintained.</p><p>&nbsp;</p><p>If severe or persistent hypotension occurs, hypovolemia should be considered, and the condition should be managed with appropriate parenteral fluid therapy.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Analgesics, Opioids, phenylpiperidine derivatives,</p><p>ATC code: N02AB03</p><p><em>&nbsp;</em></p><p>Mechanism of action</p><p>Fentanyl is an opioid analgesic, interacting predominantly with the &micro; opioid receptor. Its primary therapeutic actions are analgesia and sedation.&nbsp;</p><p>&nbsp;</p><p>Pediatric Population</p><p>The safety of DUROGESIC was evaluated in 3 open-label studies in 289 pediatric subjects with chronic pain, aged 2 to 17 years, inclusive. Eighty of the children were aged 2 to 6 years, inclusive. Of the 289 subjects enrolled in these 3 studies, 110 initiated DUROGESIC treatment with a dosage of 12 mcg/h. Of these 110 subjects, 23 (20.9%) had previously been receiving &lt;30 mg of oral morphine equivalents per day, 66 (60.0%) had been receiving 30 to 44 mg of oral morphine equivalents per day, and 12 (10.9%) had been receiving at least 45 mg of oral morphine equivalents per day (data not available for 9 [8.2%] subjects). Starting dosages of 25 mcg/h and higher were used by the remaining 179 subjects, 174 (97.2%) of whom had been on opioid doses of at least 45 mg of oral morphine equivalents per day. Among the remaining 5 subjects with a starting dosage of at least 25 mcg/h whose prior opioid doses were &lt;45 mg of oral morphine equivalents per day, 1 (0.6%) had previously been receiving &lt;30 mg of oral morphine equivalents per day and 4 (2.2%) had been receiving 30 to 44 mg of oral morphine equivalents per day (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>DUROGESIC provides continuous systemic delivery of fentanyl during the 72-hour application period. Following DUROGESIC application, the skin under the system absorbs fentanyl, and a depot of fentanyl concentrates in the upper skin layers. Fentanyl then becomes available to the systemic circulation. The polymer matrix and the diffusion of fentanyl through the layers of the skin ensure that the release rate is relatively constant. The concentration gradient existing between the system and the lower concentration in the skin drives drug release. The average bioavailability of fentanyl after application of the transdermal patch is 92%.</p><p>&nbsp;</p><p>After the first DUROGESIC application, serum fentanyl concentrations increase gradually, generally leveling off between 12 and 24 hours and remaining relatively constant for the remainder of the 72-hour application period. By the end of the second 72-hour application, a steady-state serum concentration is reached and is maintained during subsequent applications of a patch of the same size. Due to accumulation, the AUC and C<sub>max</sub> values over a dosing interval at steady state are approximately 40% higher than after a single application. Patients reach and maintain a steady-state serum concentration that is determined by individual variation in skin permeability and body clearance of fentanyl. High inter-subject variability in plasma concentrations has been observed.</p><p>&nbsp;</p><p>A pharmacokinetic model has suggested that serum fentanyl concentrations may increase by 14% (range 0-26%) if a new patch is applied after 24 hours rather than the recommended 72-hour application.</p><p>&nbsp;</p><p>Skin temperature elevation may enhance the absorption of transdermally-applied fentanyl (see section</p><p>4.4). An increase in skin temperature through the application of a heating pad on low setting over the</p><p>DUROGESIC system during the first 10 hours of a single application increased the mean fentanyl AUC value by 2.2-fold and the mean concentration at the end of heat application by 61%.</p><p>&nbsp;</p><p>Distribution</p><p>Fentanyl is rapidly distributed to various tissues and organs, as indicated by the large volume of distribution (3 to 10 L/kg after intravenous dosing in patients). Fentanyl accumulates in skeletal muscle and fat and is released slowly into blood.&nbsp;</p><p>&nbsp;</p><p>In a study in cancer patients treated with transdermal fentanyl, plasma protein binding was on average 95% (range 77-100%). Fentanyl crosses the blood-brain barrier easily. It also crosses the placenta and is excreted in breast milk.</p><p>&nbsp;</p><p>Biotransformation</p><p>Fentanyl is a high clearance active substance and is rapidly and extensively metabolized primarily by CYP3A4 in the liver. The major metabolite, norfentanyl, and other metabolites are inactive. Skin does not appear to metabolize fentanyl delivered transdermally. This was determined in a human keratinocyte cell assay and in clinical studies in which 92% of the dose delivered from the system was accounted for as unchanged fentanyl that appeared in the systemic circulation.</p><p>&nbsp;</p><p>Elimination</p><p>Following a 72-hour patch application, the mean fentanyl half-life ranges from 20 to 27 hours. As a result of continued absorption of fentanyl from the skin depot after removal of the patch, the half-life of fentanyl after transdermal administration is about 2- to 3-fold longer than intravenous administration.</p><p>&nbsp;</p><p>After intravenous administration, fentanyl mean total clearance values across studies range in general between 34 and 66 L/h.</p><p>&nbsp;</p><p>Within 72 hours of IV fentanyl administration, approximately 75% of the dose is excreted into the urine and approximately 9% of the dose into the faeces. Excretion occurs primarily, as metabolites, with less than 10% of the dose excreted as unchanged active substance.&nbsp;</p><p>&nbsp;</p><p>Linearity/non-Linearity</p><p>The serum fentanyl concentrations attained are proportional to the DUROGESIC patch size. The pharmacokinetics of transdermal fentanyl do not change with repeated application.</p><p>&nbsp;</p><p>Pharmacokinetic/Pharmacodynamic Relationships</p><p>There is a high inter-subject variability in fentanyl pharmacokinetics, in the relationships between fentanyl concentrations, therapeutic and adverse effects, and in opioid tolerance. The minimum effective fentanyl concentration depends on the pain intensity and the previous use of opioid therapy. Both the minimum effective concentration and the toxic concentration increase with tolerance. An optimal therapeutic concentration range of fentanyl can therefore not be established. Adjustment of the individual fentanyl dose must be based on the patient&rsquo;s response and level of tolerance. A lag time of 12 to 24 hours after application of the first patch and after a dose increase must be taken into account.</p><p>&nbsp;</p><p>Special populations</p><p><em>&nbsp;</em></p><p>Elderly</p><p>Data from intravenous studies with fentanyl suggest that elderly patients may have reduced clearance, a prolonged half-life, and they may be more sensitive to the drug than younger patients. In a study conducted with DUROGESIC, healthy elderly subjects had fentanyl pharmacokinetics which did not differ significantly from healthy young subjects although peak serum concentrations tended to be lower and mean half-life values were prolonged to approximately 34 hours. Elderly patients should be observed carefully for signs of fentanyl toxicity and the dose reduced if necessary (see section 4.4).</p><p>&nbsp;</p><p>Renal impairment</p><p>The influence of renal impairment on the pharmacokinetics of fentanyl is expected to be limited because urinary excretion of unchanged fentanyl is less than 10% and there are no known active metabolites eliminated by the kidney. However, as the influence of renal impairment on the pharmacokinetics of fentanyl has not been evaluated, caution is advised (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p>Hepatic impairment</p><p>Patients with hepatic impairment should be observed carefully for signs of fentanyl toxicity and the<br />dose of DUROGESIC should be reduced if necessary (see section 4.4). Data in subjects with cirrhosis<br />and simulated data in subjects with different grades of impaired liver function treated with transdermal<br />fentanyl suggest that fentanyl concentrations may be increased, and fentanyl clearance may be<br />decreased compared to subjects with normal liver function. The simulations suggest that the steadystate<br />AUC of patients with Child-Pugh Grade B liver disease (Child-Pugh Score = 8) would be<br />approximately 1.36 times larger compared with that of patients with normal liver function<br />(Grade A; Child-Pugh Score = 5.5). As for patients with Grade C liver disease<br />(Child-Pugh Score = 12.5), the results indicate that fentanyl concentration accumulates with each<br />administration, leading these patients to have an approximately 3.72 times larger AUC at steady state.</p><p>Pediatric Population</p><p>Fentanyl concentrations were measured in more than 250 children aged 2 to 17 years who were applied fentanyl patches in the dose range of 12.5 to 300 mcg/h. Adjusting for body weight, clearance (L/h/kg) appears to be approximately 80% higher in children 2 to 5 years old and 25% higher in children 6 to 10 years old when compared to children 11 to 16 years old, who are expected to have a similar clearance as adults. These findings have been taken into consideration in determining the dosing recommendations for pediatric patients (see sections 4.2 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity.</p><p>&nbsp;</p><p>Standard reproductive and developmental toxicity studies have been carried out using parenteral administration of fentanyl. In a rat study fentanyl did not influence male fertility. Some studies with female rats revealed reduced fertility and enhanced embryo mortality.</p><p>&nbsp;</p><p>Effects on the embryo were due to maternal toxicity and not to direct effects of the substance on the developing embryo. There was no indication of teratogenic effects in studies in two species (rats and rabbits). In a study on pre- and postnatal development the survival rate of offspring was significantly reduced at doses which slightly reduced maternal weight. This effect could either be due to altered maternal care or a direct effect of fentanyl on the pups. Effects on somatic development and behavior of the offspring were not observed.</p><p>&nbsp;</p><p>Mutagenicity testing in bacteria and in rodents yielded negative results. Fentanyl induced mutagenic effects in mammalian cells <em>in vitro</em>, comparable to other opioid analgesics. A mutagenic risk for the use of therapeutic doses seems unlikely since effects appeared only at high concentrations.</p><p>&nbsp;</p><p>A carcinogenicity study (daily subcutaneous injections of fentanyl hydrochloride for two years in Sprague Dawley rats) did not induce any findings indicative of oncogenic potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Backing Layer: Film, Polyester/Ethylene Vinyl Acetate Copolymer,<br />Protective Liner: Film, Siliconized Polyester, Drug<br />Layer: Polyacrylate Adhesive.<br />Inks (on backing):<br />DUROGESIC 12 &mu;g/hour<br />Printing Ink, Orange.<br />DUROGESIC 25 &mu;g/hour<br />Printing Ink, Red<br />DUROGESIC 50 &mu;g/hour<br />Printing Ink, Green<br />DUROGESIC 75 &mu;g/hour<br />Printing Ink, Blue<br />20<br />DUROGESIC 100 &mu;g/hour</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>To prevent interference with the adhesive properties of DUROGESIC, no creams, oils, lotions or<br />powder should be applied to the skin area when the DUROGESIC transdermal patch is applie</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original pouch, in order to protect from light.<br />This medicinal product does not require any special temperature storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each patch is packed in a heat-sealed pouch. The pouch material is a lamination of polyethylene<br />terephthalate (PET), low density polyethylene (LDPE), aluminium foil, adhesive and acrylonitrile<br />film.<br />DUROGESIC is supplied in cartons containing 3, 4, 5, 8, 10, 16, 20 or 30 individually packed patches.<br />Not all pack sizes may be marketed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Instructions for disposal:<br />Used patches should be folded so that the adhesive side of the patch adheres to itself and then they<br />should be safely discarded. Any unused medicinal product or waste material should be disposed of in<br />accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Janssen Cilag, Belgium  
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 June 2019 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>